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Combination anti-retroviral drug therapy (ART) significantly suppresses
HIV-1 viremia in most infected individuals, but is incapable of curing disease. The
major barrier to HIV-1 cure is a population of long-lived cells that harbor
replication-competent provirus and are refractory to current therapies—termed
the latent reservoir. New therapeutic approaches to clear latent HIV-1-infected
cells are necessary to achieve cure. In the first part of this thesis, I show that
HIV-1 mutates and diversifies at the expected rate within humanized mice (humice) and that hu-mice can sustain HIV-1 viremia for up to 4 months, thus
allowing hu-mice to be used as a small animal model to study HIV-1
therapeutics. Using hu-mice, I show that when administered as single agents,
recently discovered broadly neutralizing monoclonal antibodies (bNAbs) induce
selective pressure at restricted viral epitopes. This causes a transient drop in
viremia and the rapid emergence of viral escape mutants. When bNAbs are
administered in combinations that target at least three independent epitopes, the
emergence of viral escape variants is prevented.
In the second part of this thesis, I show that viremia returns in hu-mice
when antibody concentrations drop beneath their therapeutic thresholds. But the
rebounding viruses do not carry signature escape mutations and are still

sensitive to antibody neutralization. This suggests silently infected cells persist in
hu-mice. I use hu-mice to assess viral eradication regimens that combine
antibody therapy with latency reversal agents (LRAs). I show that a combination
of bNAbs plus a combination of LRAs prevent viral rebound in humanized mice.
To determine if antibodies play a unique role in clearing latently infected cells, I
compared antibodies to ART for their efficacy in preventing viral rebound. I found
that antibodies were more effective than ART at preventing viral rebound, and
that this effect depended on intact Fc-FcR interactions. Within the limitations of
the model, these studies provide proof of principle that antibodies combined with
LRAs can be used to clear the latent reservoir in humanized mice and should be
explored in other models.
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CHAPTER 1:
INTRODUCTION

Human Immunodeficiency Virus (HIV) infection is incurable and requires
lifelong combination antiretroviral therapy (ART) to keep viral replication in check.
In the absence of therapy, infection leads to high viral loads and gradual loss of
target CD4+ T cells that culminates in Acquired Immunodeficiency Syndrome
(AIDS). While ART can significantly suppress viremia and slow the progression
of disease, ART cessation leads to rapid virological relapse. The major obstacle
to a cure is a population of infected cells that harbor replication-competent,
integrated provirus—termed the latent reservoir. The latent reservoir forms very
early after infection, remains stable in size over time, and is refractory to both
ART and HIV-1 specific immune responses. Despite its success, ART requires
daily dosing, has adverse side effects, is susceptible to viral resistance, and is
not universally accessible, making curative therapies highly desirable. A single
case of an HIV-1 cure has been reported, but it involved a treatment regimen that
carries a high risk of mortality and is impossible to implement on a broader scale.
While the single reported cure case provides proof of concept that reservoir
eradication is possible, there are still significant gaps in our molecular
understanding of the viral reservoir and how to target it to achieve prolonged viral
remission and cure. These problems are exacerbated by the lack of small animal
models to facilitate latency studies and potential therapeutic interventions. My
work demonstrates that humanized mice can be used as a model to study HIV-1
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therapy and I use this model to evaluate the effects of broadly neutralizing
antibodies (bNAbs) against HIV-1. I extend this analysis to investigate bNAbs’
ability to impact the establishment, and maintenance of the latent reservoir within
humanized mice.

1.1 Course of HIV Infection

HIV can be transmitted through sexual contact at mucosal interfaces,
blood, or mother-to-child. Regardless of transmission route, the virus infects
target CD4+ T cells, rapidly expands within lymph nodes, and disseminates into
the periphery within days. Viremia usually peaks 3-4 weeks following
transmission, reaching viral loads up to 107 copies per ml. During the early phase
of infection, individuals typically experience an acute HIV syndrome,
characterized by flu-like symptoms, fever, and lymphadenopathy(Moir et al.,
2011; Pantaleo et al., 1993). Following peak viremia, viral loads decrease with
the onset of the cytotoxic CD8+ T lymphocyte (CTL) response. The onset of a
CTL response induces rapid selection of viral escape mutants—identified by
amino acid changes clustered within CD8+ T cell recognition
epitopes(Goonetilleke et al., 2009; Turnbull et al., 2009). Neutralizing antibodies
against the viral envelope glycoprotein (Env) emerge ~12 weeks after infection
and impose immune pressure selecting for viral variants with mutations in Env
that mediate antibody-escape(Gray et al., 2007; Richman et al., 2003; Wei et al.,
2003). The antibody response evolves to bind and neutralize the newly escaped
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virus, but new escape variants quickly emerge and completely replace the
antibody-sensitive strains in circulation, leading to successive rounds of antibody
neutralization and viral escape(Richman et al., 2003; Wei et al., 2003).
Eventually an equilibrium between immune pressure and viral turnover is
reached ~3-6 months after infection and viremia settles at a stable level known
as the viral set point. Set point viral loads are typically between 103 and 105
copies/ml. However there is wide variation, and higher set points are predictive
for faster disease progression(Fauci and Lane, 2012; Mellors et al., 1996). By the
time viral set point is reached, the infection has progressed to the chronic phase,
where symptoms typically subside in what is called clinical latency. Despite the
absence of symptoms, viral replication and turnover remain high, causing
continued depletion of CD4+ T cells and immune dysreglulation(Lane et al., 1983;
Moir et al., 2011).
Homeostatic mechanisms to maintain adequate immune cell populations
cannot keep pace with virally-mediated cell death and chronic infection leads to
progressive immunological decline. This decline is characterized by increasing
susceptibility to infection-related cancers and pathogens normally cleared by an
immune-competent adult. Contraction of these diseases indicates the end of
clinical latency, and untreated individuals usually die within 1 year of contracting
an opportunistic infection. Overall, patients left untreated typically develop stage
3 AIDS within 8-10 years of HIV infection, and the median time to death following
seroconversion is ~11 years, but it is clade dependent(Markowitz et al., 2003;
Otten et al., 2000; Todd et al., 2007; UNAIDS, 2007).

3

1.2 Therapy Against HIV-1

Current therapy for HIV-1 is combination antiretroviral therapy (ART),
which consists of three different drugs that target various stages of the viral life
cycle. The major stages targeted are viral entry, reverse transcription, integration,
viral packaging and budding. The necessity for drug cocktails was suggested by
the rapid emergence of drug-resistant virus in patients who received
azidothymidine (AZT), the first approved anti-HIV-1 drug(Boucher et al., 1990).
Even dual therapy with AZT and the second approved anti-HIV-1 drug,
didanosine (DDI), was shown to be no more effective than AZT alone(Saravolatz
et al., 1996). However, triple therapy that included a protease inhibitor drug was
shown to block viral replication and suppress viral loads to undetectable levels
within weeks of therapy initiation(Hammer et al., 1997; Ho et al., 1995). Blocking
viral replication dramatically slows the course of disease and restores CD4+ T
cell levels. Most patients with access to ART can manage HIV as a chronic
disease and expect a near-normal lifespan. They even have extremely low
probabilities of transmitting disease as long as their viral load is
suppressed(Cohen et al., 2011).
However, despite the success of ART, there are major shortcomings that
make new therapies highly desirable. Firstly, ART requires daily dosing and has
adverse side effects, such as impaired lipid metabolism and psychiatric events.
In addition to being inconvenient, this causes poor adherence, which can lead to
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drug resistance. Secondly, ART is expensive and not accessible in many
resource-poor countries despite extensive international efforts to make ART
more available. This is underscored by the fact that for every 10 individuals
started on ART in the developing world, 16 are newly infected(Ruelas and
Greene, 2013).
While daily dosing and adverse side effects create adherence challenges,
ART’s biggest shortcoming from a therapeutic perspective is its inability to
directly clear infected cells—it can only block new rounds of replication. While
productively infected CD4+ T cells die very quickly in vivo (half-life estimated to
be ~1.6 days(Perelson et al., 1997)), there also exists a latent reservoir of
extremely long-lived CD4+ T cells that harbor replication-competent integrated
provirus(Chun et al., 1997b; Finzi et al., 1997; Wong et al., 1997). Even after
years of viral suppression with ART, this population of cells is capable of
producing rebound viremia when ART is stopped(Davey et al., 1999). This
makes ART a lifelong therapy and necessitates alternative therapies that can
directly kill infected cells and accelerate the clearance of the latent reservoir.
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1.3 The Latent Reservoir

The latent reservoir is the largest barrier to HIV cure and the success of
eradication strategies is likely to hinge on their abilities to sufficiently clear this
reservoir.

1.3.1 Dynamics and Kinetics of the Latent Reservoir
While the precise timing of reservoir establishment is unknown in humans,
studies from non-human primates (NHPs) suggest the reservoir is established as
early as 24-72 hours after intravenous (i.v.) infection(Tsai et al., 1998; 1995), and
36-72 hours after vaginal or rectal infection(Otten et al., 2000; Whitney et al.).
The timing of reservoir establishment has been determined by administering ART
to macaques at variable times after viral exposure and monitoring for viral
acquisition upon ART cessation. ART as post-exposure prophylaxis (PEP) is fully
protective in macaques when administered within 24 hours of i.v. exposure for at
least 4 weeks, but only partially effective when initiated 48 hours after exposure.
Even when ART is maintained for 6 months after initiation 72 hours following
rectal transmission, 4 of 4 monkeys have rebound viremia(Whitney et al., 2014).
Because the complete viral generation time is estimated to be ~2 days in
vivo(Markowitz et al., 2003) and ART can block new rounds of replication, these
experiments suggest HIV latency is established in some of the earliest infected
cells.
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While NHP models suggest CD4+ T cells found in Gut Associated
Lymphoid Tissue (GALT) are critical for early viral spread and latency
establishment(Haase, 2010), the full cellular composition of the latent reservoir
during both acute and chronic phases of infection remains an ongoing debate.
While macrophages and follicular dendritic cells have been implicated as longterm cellular depots of virus, most cell types tested for longevity following HIVinfection have half-lives less than 2-6 weeks in vivo—making them unlikely to
contribute to the clinically relevant reservoir(Ruelas and Greene, 2013)—there .
Resting memory CD4+ T cells containing integrated, replication-competent
provirus are the best-established source of a stable reservoir. It is estimated that
~1/106 resting memory CD4+ T cells are latently infected, yielding a total of ~105107 latently infected CD4+ T cells in an individual(Chun et al., 1997a; Finzi et al.,
1997). The estimated half-life of these latently infected cells varies widely from 6
months to 10+ years depending on the patient, ART regimen, and the
quantitation assay(Finzi et al., 1999; Ramratnam et al., 2000; 2004; Siliciano et
al., 2003). Regardless of the precise half-life, it is agreed that cells composing
the latent reservoir are very stable, and using an estimated half-life of ~44
months, current models estimate eradication of this reservoir solely with ART will
require >60 years of continuous therapy(Siliciano et al., 2003). However, there is
still no rapid, precise assay to measure the size of the latent reservoir—making it
very difficult to evaluate clinical interventions. Furthermore, the rarity of latent
cells makes them very difficult to study in vivo and there is no established small
animal model system to facilitate this.
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In addition to the sheer size and longevity of the reservoir, additional
hurdles to reservoir eradication include: (1) the possibility of viral spread in the
presence of ART due to cell-cell viral infection that is more efficient than cell-free
virus(Sigal et al., 2011), (2) drug-free or “immunologically privileged” sanctuaries
in the body that allow viral spread
(Fukazawa et al., 2015; Sigal and Baltimore, 2012), (3) homeostatic proliferation
of CD4+ T cells containing HIV provirus(Chomont et al., 2009) and (4)
underestimation of the true reservoir size due to inaccurate reservoir
measurement assays(Ho et al., 2013).
The dynamic interaction between latently infected cells and ongoing
immune responses further complicates efforts to clear it. Despite the early
establishment of the reservoir and predominant belief that resting cells harbor
provirus, recent studies show the reservoir’s composition is far less static than
previously recognized. It has been shown that patients who begin ART during
acute infection (<3 months after transmission) have a reservoir composed of
wild-type Gag sequences at epitopes targeted by CTLs(Deng et al., 2015).
Whereas patients that start ART in the chronic phase of infection (>3 months
after transmission) have a reservoir composed of mutated/escaped sequences
within CTL-targeted Gag epitopes. The findings show that although the reservoir
is established within days of infection, the viral sequences archived in the viral
reservoir reflect the ongoing dynamics between viral replication and immune
responses.
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In total, it is clear that existing ART is not enough to eliminate the latent
reservoir in a clinically meaningful time period. In fact, ART intensification studies
that include additional ART drugs on top of the conventional triple therapy fail to
affect reservoir size(Dinoso et al., 2009; Gandhi et al., 2010). From a therapeutic
perspective, strategies to accelerate the reduction of the latent reservoir are
required to have a clinical impact and in vivo model systems are needed to
facilitate their discovery.

1.3.2 The only known cure
While the dynamics and kinetics of the latent reservoir make eradication a
daunting task, a single reported case of HIV cure provides proof of
concept(Hütter et al., 2009). Timothy Brown, also known as the Berlin Patient,
was diagnosed with HIV in 1995 and began ART ~6 years later. He received two
doses of total body irradiation and two stem cell transplants from a human
leukocyte antigen (HLA)-identical donor who was homozygous for the CCR5Δ32
mutation that prevents viral entry from R5 tropic HIV strains. ART was stopped
just prior to the first transplant, and viremia has remained undetectable for over 5
years. Despite the fear that X4 tropic strains would emerge, it has not occurred.
While the extent of reservoir reduction attributable to the total body
irradiation (TBI) alone was initially unknown, subsequent case studies reveal TBI
alone is insufficient for eradication. Two patients who received stem cell
transplant from a non-CCR5Δ32 donor experienced viral rebound 12 and 32
weeks, respectively, after ART treatment interruption(Henrich et al., 2014). In
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total, the Berlin patient demonstrates that eradication is possible, but both
irradiation and bone marrow transplant from an HIV-resistant donor is necessary.
These procedures are risky and non-scalable. Bone marrow transplant alone
carries a 7-30% mortality risk and only ~1% of the Caucasian population has the
CCR5Δ32 mutation. A different approach is needed to eradicate the latent
reservoir for more patients, yet an efficient way to target HIV latency remains
unknown. A better understanding of latency on the molecular level is necessary
for improved targeting.

1.3.3 Molecular Understanding of HIV Latency
Postintegration HIV latency refers to the proviral reservoir formed within
resting memory CD4+ T cells, as opposed to pre-integration latency that exists in
the form of cytoplasmic linear viral cDNA or nuclear episomal viral DNA. Preintegration latent virus is significantly more labile than the post-integration form
and usually degrades within days to weeks(Pierson et al., 2002; Sharkey et al.,
2005), making it unlikely to contribute to virological relapse after long-term ART.
The predominant model for post-integration latency establishment is a three-step
process: (1) Naïve CD4+ T cells become activated in response to antigen. (2) As
they revert to a resting, memory state, they become infected by rare chance, and
(3) due to the reduced permissiveness of HIV-1 gene expression in a resting
state, integrated provirus persists for a very long time(Eisele and Siliciano, 2012;
Siliciano and Greene, 2011). This model is supported by the finding that latent
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HIV is found in memory CD4+ T cells, but to a much lesser extent in naïve CD4+
T cells(Brenchley et al., 2004; Eisele and Siliciano, 2012).
However, the model has never been empirically verified and cannot
completely account for all experimental observations. For instance, the NHP
model shows that resting CD4+ T cells are some of the first cells infected and can
potentially seed the reservoir(Zhang et al., 1999b). There is no evidence for a
transition from an activated to a resting state in these cells. Furthermore, the
model implies that cellular activation should reverse latency, yet the vast majority
of proviruses do not become transcriptionally active in response to cellular
activation(Cillo et al., 2014; Ho et al., 2013).
An alternative model of latency has been proposed that attempts to
reconcile these issues. The alternative model argues that intrinsic properties of
the virus—namely viral transactivator (Tat) protein—determine latency fates, as
opposed to cell activation state(Razooky et al., 2015). However, the evidence for
this model is limited to in vitro systems and computational modeling, making it
difficult to evaluate its relevance. In short, it is clear that our molecular
understanding of the reservoir is significantly lacking and we do not know all the
factors governing viral silencing and viral activation. This significantly hampers
our ability to manipulate virus expression and access the latent reservoir for
eradication strategies.
However, some host-cell factors and pharmacological compounds that
influence viral expression are known, which provides leads for potential ways to
reverse latency. The best understood block on viral transcription is epigenetic
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silencing. Nucleosomes 1 and 2 (nuc-1 and nuc-2) consistently form within the 5’
LTR of integrated provirus(Shirakawa et al., 2013) and suppress transcription.
Additionally, several transcription factors have been shown to recruit histone
deacetylases (HDACs) to the HIV promoter. The importance of HDAC activity is
highlighted by the ability of HDAC inhibitors to reverse HIV latency by stimulating
viral transcription both in vitro and in vivo(Archin et al., 2012; Wei et al., 2014).
Host-cell factors nuclear factor of activated T cells (NFAT) and nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) have been shown
to be positive regulators of viral transcription. At rest, NF-κB exists as a p50/RelA
heterodimer in the cytoplasm, while p50/p50 homodimers bind to the LTR in the
nucleus and prevent transcription. The p50/RelA heterodimers are required to
move to the nucleus to recruit histone acetyl-transferases (HATs) to promote
transcription. Once in the nucleus, RelA initiates transcription by interacting with
the Cdk7 kinase subunit of Transcription Factor II Human (TFIIH) and with
positive transcription elongation factor b (P-TEFb) to phosphorylate RNA Pol II
and mediate transcriptional elongation.
The role of NFAT in viral transcription is driven through the protein kinase
C (PKC) pathway, in which Ca2+ release stimulates calcineurin to
dephosphorylate NFAT, leading to NFAT nuclear localization and binding to the
5’ LTR. Phorbol esters such as prostratin are some of the most potent inducers
of HIV viral transcription by PKC-mediated activation. Because PKC activation is
a downstream consequence of T cell activation through the antigen receptor,
CD3/CD28 cross-linking also stimulates viral transcription through this pathway.
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However, only a small fraction of full-length provirus is activated from resting
CD4+ T cells despite uniform cellular activation with PHA and CD3/CD28 crosslinking(Cillo et al., 2014; Ho et al., 2013), indicating either general stochasticity of
viral reactivation or other missing factors besides cellular activation.
In addition to host-cell factors, the viral protein Tat plays a role in
regulating viral transcription. In the absence of Tat, most transcripts terminate
prematurely. Whereas in the presence of Tat, 99% of transcripts reach fulllength(Kao et al., 1987). This is because Tat binds the transactivation-responsive
element (TAR) within the 5’ end of HIV transcripts and recruits the P-TEFb
complex to remove the blocking effect of negative elongation factor (NELF). The
importance of Tat and the P-TEFb complex is highlighted by compounds that
disrupt their interactions. Bromodomain containing protein 4 (Brd4) can bind PTEFb and prevent its interaction with Tat, thus blocking transcription(Zhu et al.,
2012). Brd4 inhibitors such as JQ1 and I-BET that remove this block have been
shown to stimulate viral transcription from latent cells(Boehm et al., 2013; Li et
al., 2012; Zhu et al., 2012).
While the agents that reverse latency mentioned above show promise, our
understanding of HIV integration and latency maintenance is mostly derived from
transformed cell lines, so its translation to latency in vivo remains unclear. This is
highlighted by our inability to come up with a comprehensive paradigm for HIV
latency. Our limited understanding of reservoir eradication and latency reversal
strategies in vivo comes from clinical trials that used pharmacologic agents in
attempts to reduce the size of the latent reservoir.
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1.4 Shock and Kill Approach

Considering the stability, size, and rapid establishment of the latent
reservoir, it is commonly believed a strategy that accelerates reservoir reduction
is required to achieve a functional cure. Because latently infected cells do not
express viral antigen, they are invisible to the immune system. And although
productively infected cells die rapidly, the natural rate of activation of latently
infected cells is too low to meaningfully reduce reservoir size. The “shock and
kill” approach aims to solve these problems by stimulating latently infected cells
to express viral antigen so that they either die by cytopathic effects or are killed
by the immune system. Infection spread is prevented by maintaining antiretroviral
therapy(Deeks, 2012).
The strategy has been tested clinically a number of ways (Table 1). The
first trials used IL-2, which has been shown to activate T-cells and stimulate HIV1 production in vitro. Although IL-2 stimulated CD4+ T cell proliferation, it did not
reduce proviral DNA or infectious units per million (IUPM) (Dybul et al., 2002;
Stellbrink et al., 2002). Patients who received anti-CD3 antibody plus IL-2
showed activation and proliferation of T cells along with transient increases in
HIV RNA levels. However, there was no reduction in reservoir size and the
therapy resulted in long-lasting depletion of CD4+ T cells as well as other toxic
side effects(C et al., 2000; Van Praag et al., 2001). Together, these results led
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investigators to shift to latency reversal agents that did not induce global cellular
activation.
HDAC inhibitors were the first class of non-global T-cell activator LRAs to
be tested. In the first test, ART intensification using enfuvirtide plus valproic acid
was shown to reduce infection units per billion resting CD4+ T cells by a mean of
63% in four patients and the study claimed that reservoir half-life decreased from
~44 months to 10 months(Lehrman et al., 2005). However, follow up studies that
analyzed larger numbers of patients who had been receiving ART plus long-term
valproic acid for neurologic or psychiatric conditions could not detect differences
in the sizes of the latent reservoirs compared to controls(Sagot-Lerolle et al.,
2008; Siliciano et al., 2007).
Another more potent class I HDAC inhibitor suberoylanilide hydroxamic
acid (SAHA, also known as vorinostat) was also tested in human patients.
Although short-course treatment was shown to boost viral transcription in
patients as measured by increases in cell-associated unspliced Gag RNA
transcripts(Archin et al., 2012; Elliott et al., 2014), prolonged administration did
not impact the size of the latent reservoir as measured by quantitative viral
outgrowth assays(Archin et al., 2014).
Panobinostat, a pan HDAC inhibitor, recently completed phase 1/2 clinical
testing and demonstrated similar results. There were increases in cell-associated
unspliced HIV RNA, but no decreases in reservoir sizes as measured by
integrated HIV DNA and IUPM. Furthermore, the median time to viral rebound
following ART interruption in 9 patients who had received panobinostat was 17
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days—no different from historical controls(MD et al., 2014). Romidepsin, an
HDAC inhibitor estimated to be 2-3 logs more potent than vorinostat(Wei et al.,
2014) is currently completing clinical testing (ClinicalTrials.gov NCT02092116),
but the results are still pending. Additional candidate LRAs that work by
alternative mechanisms, such as disulfiram (unknown mechanism) and GS-9620
(TLR7 agonist), are also being investigated either in humans(Spivak et al., 2014),
or primary cell models(Sloan et al., 2015).
While the use of LRAs that do not induce global T cell activation are
necessary for toxicity issues, they present fundamental problems for the shock
and kill approach: Firstly, no reactivation regimen tested in vivo to date has
shown efficient latency reversal that could significantly affect the latent reservoir.
Modeling of infection dynamics suggest that a 3 to 4 log reduction in reservoir
size is required to prevent viral rebound for at least 1 year after ART
interruption(Hill et al., 2014). Vorinostat was shown to reactivate just 0.079% of
proviruses from ART-suppressed patient cells following 7 days of culture(Cillo et
al., 2014). It is clear that more efficient reactivation regimens are required to have
a clinical impact.
The second problem is how to kill reactivated cells. It is generally
assumed that reactivated cells will die by cytopathic effects because productively
infected cells have very short half-lives. However, this short half-life is
determined from infected cells with the assumption of T cell activation. Although
one school of thought is that reactivated cells will die as long as ART is on board,
it is not clear if a latent cell reactivated by a non-global T cell activator will induce
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Publication
Year

Journal

Authors

16 patients

15 patients

5 patients

20 patients

24 patients; 11
experimental, 13
controls
8 patients preselected for response
to vorinostat in vitro

4 patients

3 patients

42 patients; 21
treated, 21 controls

10 patients

3 patients

26 patients; 14
treated, 12 controls

Patients

Readout

Result

cell-associated viral RNA in
resting CD4+ T cells

all 8 patients had increase (mean 4.8) in cell-associated unspliced
Gag transcripts

HAART plus 4 daily doses of 500 mg
disulfiram

plasma HIV-1 RNA and qVOA

transient increases in plasma HIV-1 RNA in 6 patients; no consistent
changes in latent reservoir size

cell-associated viral RNA in total increase of CA-unspliced RNA in 18 of 20 patients, median 7.4 fold;
CD4+ T cells at day 14
no changes in HIV DNA, plasma viremia or IUPM
plasma HIV-1 RNA; cellno significant changes in frequency of resting CD4+ T cells
HAART plus 8 weekly cycles of vorinostat
associated viral RNA; total
harboring virus; small increases in cell-associated RNA in 3 of 5
(Monday to Wednesday)
cellular DNA; qVOA
patients
transient increases in cell-associated HIV RNA corresponding to
HAART plus 3 doses (20 mg) oral
cell-associated viral RNA, plasma
panobinostat administration; no changes in HIV DNA or IUPM; 9
panobinostat per week, every other week for viremia, total and integrated HIV
patients who underwent treatment interruption showed rapid viral
8 weeks
DNA; qVOA
rebound

HAART plus 400 mg oral vorinostat daily for
14 days

HAART plus a single dose of 400 mg oral
vorinostat

replication competent virus was isolated from all 12 patients
receiving HAART alone, but only 6 of 14 patients receiving IL-2 plus
HAART (3 of these 6 patients had culturable virus with larger
intervals of 3-18 megaunits IL-2 for 5 days
VOA with resting CD4+ T cells
numbers of input resting CD4+ T cells); both patietns who
discontuned HAART had rapid viral rebound in follow-up study
plasma viremia, lymph node (LN)
no consistent changes in plasma HIV-1 RNA; no differences in
5 mg OKT3 (days 1-5) and 2-9 megaunits
viremia, and T-cell activation; viral
infectious units per million (IUPM) resting CD4+ T cells;
rhIL-2 (days 2-6)
outgrowth assay (VOA)
severe side effects due to OKT3 and rhIL-2
5-drug HAART plus 3 courses of IL-2, 7.5
minimal changes in plasma viremia; 4 log drop in LN HIV-1 RNA;
treatment interruption, LN viral
megaunits twice a day for 5 days and 2
0.8 log drop in PBMC proviral DNA; presence of virus upon CD4+ T
RNA, PBMC DNA, cellular
courses of -interferon 100 µg every other
cell co-culture; viral rebound within weeks in 2 patients who
activation
day for 2 weeks
underwent treatment interruption
viremia in peripheral blood (PB),
8 cycles of 9 megaunits IL-2 daily for 5 days,
lymphoid tissue, CSF;
no effect on proviral DNA in PB or on rebound viremia; IL-2
6 wks apart, beginning 4 wks after initiating
proviral DNA;
significantly increased CD4+ T cell counts
HAART
treatment interruption
no significant changes in plasma viremia; no effect on viral rebound
didanosine, hydroxyurea for 1 month, then
plasma viremia; 2-LTR DNA
after HAART interruption; one patient had increase in 2-LTR HIV
400 µg OKT3, and IL-2 during HAART
circles; treatment interruption
DNA circles after OKT3/IL-2 administration
HAART plus 500-750 mg oral valproic acid,
quantitative VOA (qVOA)
reduction in Infectious Units Per Billion in 3 of 4 patients
twice daily for 3 months
total and integrated HIV-1 DNA;
HAART plus valproic acid for >2 years for
no significant difference between experimental group and controls
qVOA; treatment interruption for
seizures
for any paramter measured
3 patients

Intervention

Table 1. Shock and kill trials in humans

cell death with the same kinetics as productively infected cells. To this point, it
has been shown that CD4+ T cells from ART-suppressed patients did not die
following vorinostat reactivation alone(Shan et al., 2012). Rather, CD8+ T cells
had to be stimulated with Gag peptides to induce killing of cells whose latent
state was reversed with vorinostat. This requirement for robust, functional CTL
responses to kill reactivated cells is problematic in HIV-infected patients. For one,
CTL activity declines over time as part of the general immune dysregulation of
HIV infection, and the latent reservoir often harbors provirus that has already
escaped a patient’s CTL responses(Deng et al., 2015). Secondly, it has been
shown that HDAC inhibitors interfere with CTL responses by reducing their
interferon-γ production, proliferation, and ability to kill HIV-infected primary CD4+
T cells(Jones et al., 2014). In all, both the “shock” and “kill” arms of the “shock
and kill” approach require major advances for clinical impact, highlighting the two
most important questions for HIV eradication research: (1) how can we improve
latency reversal efficiency? And (2) how do we kill latent cells?
This thesis explores the use of broadly neutralizing antibodies as a novel
anti-HIV-1 therapeutic that can suppress viremia and kill HIV-infected cells. We
show that combinations of latency reversal agents are significantly more effective
than single LRAs and when combined with bNAbs in a shock and kill approach in
vivo, viral rebound from the reservoir in hu-mice is significantly reduced.

18

CHAPTER 2:
RESULTS

2.1 Humanized Mice

To test the efficacy of bNAbs in vivo, we utilized a humanized mouse
system that has been reported previously(Brehm et al., 2010; Henrich et al.,
2014; Traggiai et al., 2004). Briefly, NOD/Rag1-/-IL2rg-/- mice irradiated at birth
and reconstituted with 2✕105 CD34+ fetal liver hematopoietic stem cells (HSCs)
were screened for the presence of human CD4+ T cells 8-12 weeks later (Fig. 1)
Mice with detectable human CD4+ T cells were infected with ~60ng p24 HIV-1YU2
by intraperitoneal (i.p.) injection and allowed 2-3 weeks for viremia to spread and
diversify. Prior to antibody administration, mice developed stable plasma viral
loads between 103 and 107 copies/ml (geometric mean 1.06✕105).
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Figure 1. Generation of humanized mice (A) Schematic of hu-mouse
generation (B) Human reconstitution of mice. Percentage of human CD45+ cells
among mouse and human CD45+ cells in the peripheral blood prior to HIV
infection (Left) and percentage of human CD4+ T cells among the human CD45+
cells (Right).
2.2 Viral diversification

To determine the rate of viral diversification, I cloned and sequenced
gp120 within the mice when there was no selection pressure. I found an average
of 2.9 mutations per 1400 base pairs sequenced attributable to viral mutation at
28 days following infection (Fig. 2). Assuming the HIV-1 generation time in vivo is
2 days(Markowitz et al., 2003), I calculate the mutation rate to be 1.5✕10-4 in this
system, consistent with diversification rates reported previously(Ince et al., 2010;
Mansky and Temin, 1995).
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Figure 2. Viral diversification in untreated mice. (A) gp120 clones from
untreated mice are shown by horizontal gray bars. Red ticks indicate nonsynonymous mutations relative to wild-type HIV-1YU2. Green ticks indicate
synonymous mutations. Sequences obtained from 9 different mice, indicated on
the left. Gp120 residue numbering according to HXB2 strain. (B) Number of
mutations observed in gp120 due to polymerase error during PCR amplification
compared to number of mutations observed in clones obtained from mouse
plasma. Two different polymerases were used for testing polymerase error. HIV1YU2 plasmid was used as the amplification template.
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2.3 Antibody escapes in vivo

It was previously reported that rapid escape to single antibodies quickly
emerges in humanized mice(Poignard et al., 1999). To see if this held true for
newly identified bNAbs, viremic hu-mice were administered one of five different
bNAbs: 45-46G54W, PG16, 3BC176, PGT128, and 10-1074(Diskin et al., 2011;
Klein et al., 2012; Mouquet et al., 2012; Walker et al., 2011; 2009). The five
bNAbs were chosen based on their extensive breadth and potency in in vitro
assays, and because they were reported to target different epitopes based on
biochemical and structural analyses. However, it was unknown how the virus
would respond in vivo considering fitness costs and the number of mutations
required to reach certain amino acids.
For 4 of the 5 bNAbs, there was a transient decline in viremia followed by
rebound within 7 days (Fig. 3), suggesting viral escape. To identify the escape
routes selected by certain bNAbs, I cloned and sequenced gp120 from the
rebound viremia. I found that the viral quasi-species within each mouse was
rapidly replaced with clonal escape variants that had amino acid substitutions at
1-3 residues within gp120 (Fig. 4). Most strikingly, the escape sites detected for
each effective bNAb were shared across identically treated mice—indicating a
strong selection pressure for those escape routes, as opposed to a wide range of
chance mutations and the emergence of founder clones following population
bottlenecks. I defined recurrent mutation sites as occurring within at least 50% of
the gp120 clones sequenced within 2 or more mice. In contrast, passenger
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mutation sites were defined as occurring in multiple clones within a single mouse,
but not shared

A

Untreated

10-1074

107

107

107

106

106

106

105

105

105

104

104

104

103

103

103

102

-20

0

20

102

45-46G54W

viral load (copies/ml)

PGT128

-20

0

20

102

PG16
107

107

106

106

106

105

105

105

104

104

104

103

103

103

-20

0

20

102

-20

0

20

3BC176

107

102

-20

0

20

102

-20

0

20

days post therapy initiation

re
1 0 a te
-1 d
0
PG 7 4
T1
2
45 8
-4
6G
54
PG
W
16
3B
C1
76

Un
t

2

0

-2

log

copies/ml) at week 1

B

Figure 3. Transient viremia decline in monotherapy treated mice. (A) Plasma
viremias for untreated mice and monotherapy treated mice. Lines represent
individual mice, red arrows indicate antibody injections of 0.5 mg. Gray shading
indicates the quantitation limit for HIV-1 RNA by qRT-PCR. (B) Quantification of
drop in viral load seen in first week of antibody injections.

23

Figure 4. Monotherapy selects for recurrent escape variants across
multiple mice. Gp120 sequences shown as in Figure 2a. Blue shading highlights
recurrent mutations observed in at least 50% of clones from 2 or more mice. The
mouse from which the sequence was obtained is indicated on the y-axis.

24

across multiple mice, or as being shared across multiple mice, but occurring in
fewer than 50% of the gp120 clones. For the four effective bNAbs, 92% of gp120
clones contained a recurrent mutation.
For 45-46G54W, escape clones had recurrent mutations at residues 279,
280, or 458 (HXB2 numbering). For PG16, escape clones had mutations at
residues 160 or 162, both of which form the potential N-linked glycosylation site
(PNGS) at site 160. PGT128 and 10-1074 both had mutations at residues 332 or
334, corresponding to the PNGS at site 332 (Table 2). There was only one
recurrent mutation for 3BC176-treated mice (G471R), however only 31% of
gp120 clones from these mice had this mutation and 2 of 6 mice did not exhibit
this mutation or any other recurrent mutation—indicating significantly less
selection pressure. 3BC176 also was the lone antibody tested not to produce a
transient drop in viremia. From this, I conclude that there is a narrow range of
preferred escape sites for the effective antibodies.
Table 2. Recurrent mutations in monotherapy treated mice. Gp120 domains
and residue sites of recurrent mutations observed in vivo for each of the 5 bNAbs
tested as monotherapy.

Antibody
Monotherapy
45-46G54W
PG16
10-1074
PGT128
3BC176

gp120 domain

Recurrent Mutations

CD4bs
V1/V2 loop
glycans in base of V3 loop
V3-loop glycans
conformational/undetermined

25

276, 278, 279, 280, 281, 458
160, 162
332
332, 334
471

To verify that the recurrent mutations at a single residue detected in the
plasma actually conferred resistance as opposed to either passenger
substitutions or a combination of many mutations, I cloned the putative escape
mutations into an otherwise wild-type HIV-1YU2 pseudovirus and tested these
pseuodiviruses for sensitivity to their respective antibodies in TZM.bl assays. As
predicted, the single residues were sufficient to confer resistance (Table 3). The
lone exception was G471R, which did not confer resistance to 3BC176,
consistent with 3BC176’s inability to reduce viremia. In contrast, passenger
mutations did not confer resistance to any of the antibodies. I conclude that point
mutations at selected residues are sufficient to confer escape, and I term these
signature escapes.

Table 3. Recurrent mutation pseudovirus sensitivities in TZM.bl. IC50 values
of pseudovirus variants containing recurrent mutations or passenger mutations.
KEY

IC 50 (µg/ml) in TZM.bl neutralization assay

WT

Observed in (Mouse ID)
-

Recurrent mutation in 3BC176-treated mice
G471R
44, 55, 64, 74

3BC176

0.319 0.612 0.024 0.169 0.312

0.159 0.154 0.008

Recurrent mutation in PG16-treated mice
N160K
22, 25, 38, 43, 49, 56, 73
T162N
22, 25, 56, 79

0.145
0.154

Recurrent mutation in 45-46 G54W-treated mice
N279H
2
N280Y
25, 49, 76

0.209 0.294
0.276 0.145

>50
>50

Recurrent mutations in tri-mix treated mice
T162I-G458D
16
T162N-N280Y
25

0.275
0.138

>50
>50

Theoretical penta-mix mutations
N160K-N280Y-N332K
N160K-A281T-N332K
T162I-N280Y-N332K
T162I-N279K-N332K

0.146
0.1
0.13
0.149

>50
>50
>50
>50

0.02

>0.1 - 1

>1-10

>10-50

>50

Recurrent mutations in tri-mix treated mice
T162I-G458D
16
0.275
T162N-N280Y
25
0.138

>50
>50

14.33
>50

0.012
0.027

0.047
0.079

Theoretical penta-mix mutations
N160K-N280Y-N332K
N160K-A281T-N332K
T162I-N280Y-N332K
T162I-N279K-N332K

0.146
0.1
0.13
0.149

>50
>50
>50
>50

>50
>50
>50
>50

>50
>50
>50
>50

>50
>50
>50
>50

0.243
0.173
0.347
0.23
0.26
0.187
0.2
0.188
0.146
0.222

0.285
0.341
0.5
2.67
0.273
0.167
0.303
0.557
0.503
0.131

0.015
0.023
0.017
0.013
0.009
0.001
0.013
0.014
0.017
0.001

0.098
0.11
0.145
0.248
0.045
0.021
0.064
0.032
0.082
0.012

0.26
0.207
0.159
0.253
0.153
0.074
0.164
0.109
0.167
0.021

Recurrent mutatuions + passenger mutations
T162I-Y61H
58
0.156
T162N-V430E
79
1.67
N280Y-A174T
76
0.064
N332S-N413K
0.181

>50
>50
0.138
0.526

0.014
0.003
>50
0.017

0.088
0.037
0.01
>50

0.115
0.106
0.021
>50

0.091

0.007 0.086 0.155
0.013 0.166 0.175

>50
>50

Recurrent mutation in PGT128 or 10-1074-treated mice
N332K
135, 147, 148, 153, 154, 162 0.232 0.988 0.017
N332Y
135, 145, 162
0.269 0.632 0.01
S334N
135, 145
0.218 0.615 0.02

-

< 0.1

PG16 45-46 G54WPGT128 10-1074

0.064 0.177
0.031 0.126

>50
>50
>50

>50
13.6
7.308

14.33 0.012 0.047
>50 0.027 0.079
>50
>50
>50
>50

>50
>50
>50
>50

>50
>50
>50
>50
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-

Passenger mutations
Y61H
58
E102K
43, 64, 154
N295S
148, 154
I311M
3
S365L
15, 74
G366E
38, 44, 148, 153, 162
I371M
28, 38, 74, 148, 161
N413K
148, 154, 162
E429K
16, 33, 65
N295S-G366E-N413K
-

Although the residue locations were restricted, I extended the analysis to
determine how restricted the amino acids at each of these locations were. I
detected multiple amino acids at each site for 3 of the 4 effective bNAbs. For
PG16 and PGT128, there was remarkable tolerance of amino acid and
nucleotide substitutions. Of the 27 possible single nucleotide changes that would
eliminate the PNGS at the bNAb’s corresponding epitope, I detected 13 of them
in at least one clone. Overall, there were 7 different amino acids detected at sites
160 and 162 for PG16, and 5 different amino acids detected at sites 332 and 334
for PGT128 (Fig. 5). Considering the short time frame for escape in this
experiment, and the limited number of mice tested, the virus appears to have
sampled a large part of its mutational space at the escape residues. Thus, there
appears little restriction for which nucleotide change is selected—as long as it
eliminates the PNGS.
Similarly, despite the limited residue sites conferring escape to 45-46G54W,
there were 8 different amino acids resulting from single nucleotide changes
detected, underscoring the flexibility allowed at those residues. In contrast, the
escapes detected for 10-1074 were impressively narrow. Fifty-one of 53 clones
across four different mice all had identical N332K substitutions (Table 2 and Fig.
5). The N332K mutation conferred complete resistance to 10-1074 in TZM.bl
(IC50 > 50 µg/ml). Meanwhile, HIV-1YU2N332Y and HIV-1YU2S334N, both of which
occurred in just 1 of 53 clones, had IC50’s of 13.6 and 7.3 µg/ml, respectively.
While the N332Y and S334N escapes are approximately ~30x less sensitive to
10-1074 than wild-type HIV-1YU2, they are not completely resistant, suggesting
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the frequency of observed escapes is directly related to the sensitivity to the
corresponding antibody in this system.
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Figure 5. Amino acids detected at escape sites in monotherapy. Each pie
chart represents all the escape clones detected within monotherapy treated mice.
Different colors of the pie represent the proportion of sequences that contain a
particular amino acid at the escape site. The escape sites and the wild-type
amino acids are shown on the outside of each pie slice. The numbers inside the
centers of the pies represent the number of mice that escape clones were
obtained from, and the total number of escape clones sequenced, respectively.
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2.4 Antibody combinations

Because the selected bNAbs target distinct epitopes on the HIV-1
glycoprotein and have limited escape routes, we investigated whether treatment
with antibody combinations could prevent the emergence of escape. A tri-mix of
antibodies that targets two identifiable epitopes (PG16, and 45-46G54W, 3BC176)
was able to sustainably suppress viremia in 3 of 11 treated mice, but rapid
escape emerged in 8 of 11 mice (Fig. 6). To determine if there was a synergistic
or additive effect on allowed escape routes with combination therapy, I cloned
and sequenced gp120 from the 8 mice that escaped. All 88 sequences
simultaneously contained the signature escapes observed for PG16 and 4546G54W in monotherapy (Fig. 7). Additionally, nearly all the same amino acid
substitutions seen in monotherapy were observed during combination therapy
(Fig. 8). Testing the observed mutations in TZM.bl confirmed two signature
mutations were sufficient to confer resistance to PG16 and 45-46G54W. In
contrast, gp120 clones obtained after antibody levels decayed beneath their
therapeutic thresholds from the 3 mice that did not escape during therapy
showed mutations at either the PG16 epitope (N162P) or in the vicinity of the
confirmed 45-46G54W epitope (K282R), but never both simultaneously. From this,
I conclud that escape from bNAbs is additive.
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Figure 6. Viremias in tri-mix treated mice. Plasma viremia from 11 mice
treated with a tri-mix of bNAbs (45-46G54W, PG16, 3BC176). Antibody injections
indicated with red arrows. Lines indicate individual mice. Black indicates mice
that escaped during therapy. Blue indicates mice that did not escape.
Because ~72% of mice treated with an antibody combination that targets
two independent epitopes still show viral escape, we tested if an antibody
combination that targets three independent epitopes is sufficient to completely
prevent escape. We included 10-1074 and PGT128 into the combination
antibody mix, both of which target the N-linked glycan at position 332 according
to the monotherapy experiments. All 13 mice treated with this antibody
combination had viral loads suppressed beneath the limit of quantitation for 3
weeks (Fig. 9). However, ~21 days following antibody therapy initiation, 3 of the
13 mice had detectable viremia return even though antibodies were still being
administered. I cloned gp120 from the plasma of each of these three mice (10
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clones, 7 clones, 6 clones obtained from each mouse, respectively) and found
that all 23 clones sequenced had evidence of APOBEC3G/F mediated G to A
hypermutation that resulted in premature stop codons (Fig. 10). I found no
signature escape mutations to any of the antibodies. Although it remains
unanswered how the cells producing these viral particles persisted such that I
could repeatedly detect virus, it appears the detectable viremia does not
represent actively spreading virus, but rather infected cells producing defective
virus. From this, I conclude that a combination of antibodies that targets three
independent epitopes prevents emergence of escape variants in humanized
mice.
To determine if virus was completely cleared in mice that did not show
viral escape, we discontinued antibody therapy after 31-60 days and monitored
the mice for an additional 100 days. In 7 out of 8 mice that survived, viremia
returned. I obtained 28 gp120 clones from 5 of the rebounding mice. Three
clones showed signature escape mutations to 10-1074 and PGT128, but not to
PG16 or 45-46G54W, while the remaining clones did not show signature escape
mutations to any of the antibodies (Fig. 10). Only 1 of 28 clones showed a stop
codon likely resulting from G to A hypermutation. From this, I conclud that
replication-competent, antibody-sensitive virus persisted throughout the
treatment period and was capable of producing viral rebound.

31

Figure 7. Gp120 sequences from tri-mix treated mice. Gp120 sequences
shown as in figure 4. (A) Sequences obtained from mice that escaped during trimix therapy, showing simultaneous escape to PG16 and 45-46G54W. (B)
Sequences obtained from mice that did not escape therapy, after therapy was
discontinued and mice showed rebound viremia.
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Figure 8. Amino acids detected at escape sites in tri-mix treated mice. Pie
charts as in figure 5. All 88 clones obtained from the 8 escaped mice
simultaneously contained escape to both PG16 and 45-46G54W.
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Figure 9. Plasma viremias from penta-mix treated mice. Viremias shown for
13 mice treated with penta-mix antibodies. Injections shown with red arrows.
Black lines indicated individual mice that were suppressed beneath the
quantitation limit during therapy. Red lines indicate mice that had detectable
viremia during therapy, from which I obtained gp120 clones.
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Figure 10. Hypermutation within penta-mix treated mice. Gp120 sequences
shown as in figure 4. Asterisks indicate in-frame stop codons as a result of G to A
hypermutation. (A) gp120 clones obtained from mice during penta-mix therapy
(indicated by red viremia lines in figure 9). (B) gp120 clones obtained from mice
after therapy discontinuation when mice exhibited rebound viremia.
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2.5 Humanized mice as a model to study HIV latency

The emergence of rebound viremia after sustained suppression mimics
the clinical scenario for patients treated with ART. However, ART can only block
new rounds of viral replication, whereas bNAbs can bind and clear viral particles
directly(Chun et al., 2014; Igarashi et al., 1999). Therefore undetectable plasma
viremia in ART-suppressed patients implies there are no productively infected
cells releasing virions into the blood, whereas this possibility cannot be excluded
in bNAb-suppressed mice. To test if there are productively infected cells during
bNAb-mediated suppression, I measured cell-associated viral RNA from bNAbtreated-humanized mice with undetectable plasma viral loads. Twenty-nine of 35
samples measured across different time points from 23 suppressed mice had
undetectable cell-associated viral RNA, with the 6 detectable samples averaging
0.03 copies per cell (range 0.007 to 0.2) (Fig. 11). In contrast, untreated mice
had detectable cell-associated RNA in 12 of 15 samples, with an average of 0.7
copies per cell (range 0.1 to 5). From this, I conclude that bNAbs are not just
clearing cell-free virus, but also eliminating productively infected cells or arresting
viral production from cells.
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Figure 11. Cell-associated viral RNA mostly undetectable in
antibody suppressed mice. Cell associated viral RNA isolated
from PBMCs in antibody-treated mice with undetectable plasma
viremias (left) and untreated, viremic mice (right). Viral RNA
expressed per cell equivalent, as determined by CCR5 DNA
copies.
For ART-suppressed patients, it is believed that resting memory CD4+ T
cells comprise the primary long-lived reservoir of infected cells capable of
producing rebound viremia upon ART discontinuation(Chun et al., 1997b; Eisele
and Siliciano, 2012; Finzi et al., 1997; Wong et al., 1997). To determine if resting
CD4+ T cells capable of producing viremia exist in humanized NRG mice
suppressed with bNAb combinations, I isolated resting CD4+ T cells from 6 HIVinfected humanized mice that were suppressed with bNAb combinations and
cultured the cells using a standardized viral outgrowth assay (VOA)(Laird et al.,
2013). Six of 16 culture wells became p24+, an indicator of robust viral
production (Fig. 12). Based on the number of resting CD4+ T cells and number of
culture wells tested, I calculate ~2.2 IUPM cells(Laird et al.), a frequency
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consistent with that obtained from ART-suppressed bone-marrow, liver, thymus
(BLT) humanized mice(Denton et al., 2012) and human patients(Chun et al.,
1997a; Siliciano et al., 2003). From this, I conclude that humanized NRG mice
harbor replication-competent virus within resting CD4+ T cells in the presence of
bNAbs.
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Figure 12. Resting CD4+ T cell isolation and VOA from antibody suppressed
mice. Resting CD4+ T cells were isolated from antibody-treated humanized mice
with undetectable plasma viral loads. Mouse cells were depleted, and human
CD4+ T cells were purified by negative isolation, followed by depletion of
activated cells. Resting CD4+ T cells from identical fetal liver donors were pooled
together and cultured by VOA protocol. Cells from three different donors were
obtained and cultured separately, as indicated by vertical black lines. Individual
culture wells were tested for p24 in the supernatant by ELISA. Number inside
each well represents number of resting CD4+ T cells started in the culture.
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Because antibody-sensitive virus capable of producing rebound viremia
upon therapy cessation persists in the presence of bNAbs and humanized mice
harbor resting CD4+ T cells containing replication-competent virus, I decided to
test strategies that could prevent viral rebound by eliminating persistent viral
reservoirs.

2.6 Combination Therapy with bNAbs and Inducers

I employed a “shock and kill” approach, in which viral transcription is
induced within CD4+ T cells harboring integrated provirus. Since CD4+ T cells
harboring non-expressed provirus have very long half-lives and are
unrecognizable to immune surveillance, the goal is to induce viral transcription to
enable viral cytopathic effects or immune-mediated killing(Deeks, 2012).
Humanized mice with established HIV-1YU2 infections (viremia ranging from
4.70✕103-7.96✕105 copies/ml at 2-3 weeks after infection) were treated with a trimix of bNAbs (10-1074, PG16, 3BNC117) that could prevent escape and
suppress viremia. When plasma viremia and cell-associated HIV RNA dropped
below detection, mice were co-administered a viral inducer for 5-14 days, and
monitored for viral rebound for an additional 47-85 days (Fig. 13).
I tested three inducers: vorinostat, an HDAC inhibitor(Archin et al., 2012;
2009; Contreras et al., 2009), I-BET151, a BET protein inhibitor(Boehm et al.,
2013), and αCTLA4, a T-cell inhibitor pathway blocker. These inducers were
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selected based on their differing mechanisms of action, established safety and
pharmacokinetics in mice, and abilities to induce HIV-1 transcription in vitro.
Mice receiving antibodies plus vorinostat showed no significant differences
in viral rebound compared to mice receiving antibody alone (Fig. 13). The same
result was seen for hu-mice treated with antibodies plus I-BET151 or αCTLA4
(Fig. 13). All 10 mice that received antibody therapy plus vorinostat showed viral
rebound when the antibody dropped below therapeutic levels. Of 12 mice that
received antibody therapy plus I-BET151, 11 had viral rebound, and 10 of 11
mice that received antibody plus αCTLA4 showed viral rebound. In total, of 33
mice that received antibody plus a single inducer, 31 showed viral rebound. In
comparison, of 25 mice that received antibody therapy alone, 22 rebounded after
the level of passively administered antibody decayed below the therapeutic
threshold (p = 0.64, Fisher’s Exact Test).
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Figure 13. No difference in rebound frequency for antibodies plus a single
inducer. Mice were suppressed with combination antibodies, then administered
one of three different viral inducers while antibodies were still present, and
monitored for viral rebound. (A) Experimental schematic (B) Plasma viremias
from mice treated with antibodies alone, or antibodies plus a single inducer. Each
line represents an individual mouse. Gray indicates mice that rebound. Black
indicates mice that do not rebound by the terminal point. Antibody injections
indicated in red. Geometric mean antibody concentration across all mice in the
group shown by dashed red line. Green arrows indicate vorinostat
administrations (1.5 mg oral gavage). Purple shading indicates I-BET151
administration (30 mg/kg injections daily i.p. for 14 days). Orange arrows indicate
αCTLA4 injections (100 µg, i.p.).
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To determine whether a combination of inducers might be more effective
than a single inducer, I administered all three inducers simultaneously. In the
absence of antibody therapy, the combination of all three inducers did not abort
or noticeably alter active infection (Fig. 14A). Additionally, the human graft did not
differ between untreated mice and mice that received combination of inducers
(Fig. 14B). Twenty-three mice that initially suppressed viremia on antibody
therapy were treated with the inducers combination and followed for 62-105 days
after the last antibody injection (Fig. 15). Only 10 of the 23 mice (43%) showed
viral rebound, while the remaining 57% of mice failed to rebound, a significant
decrease in rebound frequency compared to antibody alone (p = 0.0018, Fisher’s
Exact Test), or antibody plus a single inducer (p = 0.0001, Fisher’s Exact Test).
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Figure 14. Graft and viremia unaltered by combination inducers alone. (A)
Plasma viremia in mice receiving combination inducers alone. Blue line shows
geometric mean viremia across the three mice. Arrows and shading as in figure
13. (B) Human graft as determined by flow cytometry from PBMCs.
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rebound. (A) Plasma viremia from mice administered combination inducers in
the presence of antibodies. Graph coloring and shading as in figure 14. (B)
Comparison of proportion of mice showing viral rebound by the terminal point in
mice receiving antibody alone, antibody plus any one of the three inducers, and
antibody plus the combination of all three inducers. *, p < 0.05, Fisher’s exact
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Importantly, when compared to antibody alone, neither single inducers nor
combination inducers measurably altered the frequency of CD4+ T cells
remaining at the end of the experiment, which correlated with absolute CD4+ T
cell levels (Fig. 16). Additionally, cell-associated viral RNA measured in splenic
T-cells at the terminal point supported the results from the plasma viremia levels,
with mice that failed to show viral rebound in the plasma also having
undetectable cell-associated viral RNA (Fig. 17).
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Figure 16. No difference in CD4+ T cell levels between rebounding and nonrebounding mice. (A) The % of human CD4+ T cells among all human CD45+
cells in the spleen of mice at the terminal sac, shown by treatment group and
rebound status, N.R. = non-rebounder (solid circles), Reb. = rebounder (open
circles). There was no statistically significant difference between any of the
groups, Kruskal-Wallis test. (B) correlation between the % human CD4+ T cells
among human CD45+ cells and the total number of CD4+ T cells in the spleen by
absolute count.

I measured cell-associated viral DNA as an imperfect surrogate of the
HIV-1 reservoir. HIV-1 DNA is thought to overestimate the reservoir because it
fails to exclude damaged or incomplete viral sequences that cannot be
reactivated(Ho et al., 2013). In addition, the overall number of cells assayed in
mice is limited and therefore the assay is not very sensitive. Nevertheless, I could
not detect viral DNA at the terminal point in the majority of mice that did not
rebound, whereas the majority of mice that did rebound had detectable HIV-1
DNA, with an average of 0.09 copies per T cell (Fig. 17).
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Figure 17. Cell-associated HIV-1 RNA and DNA from splenic T cells reflects
rebound status. (A) Cell-associated HIV-1 RNA measured in splenocytes at
terminal sac, expressed per cell equivalent as determined by CCR5 DNA copies.
Closed circles indicate non-rebounding mice, open circles indicate rebounding
mice. Gray shading indicates beneath detection limit. Samples above dotted line
indicate detectable HIV-1 RNA, but unreliable detection of CCR5 DNA (B) Cellassociated HIV-1 DNA. Shading and markings as in A.

When compared to controls, mice that failed to rebound after combination
antibody and inducer therapy showed similar initial plasma viremias to mice that
rebounded across all experimental groups (Fig. 18). Therefore, neither initial
viremia levels, nor CD4+ T cell levels can account for the differences between the
experimental groups.
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Figure 18. Pre-treatment viremia does not determine rebound
status. Pre-treatment viremias shown for all mice, grouped by
treatment group and rebound status. There was no statistical
difference between any of the groups, Kruskal-Wallis test.

To determine if antibody persistence accounted for differing viral rebound
outcomes, I calculated antibody levels at the time of rebound for rebounding
mice, and antibody levels at the terminal point for non-rebounding mice. The
average plasma antibody concentration at the time of viral rebound was 2.97
µg/ml, which I termed the rebound threshold (Fig. 19). Of the 18 non-rebounding
mice, the average antibody concentration at the terminal point was 0.44 µg/ml,
with 15 out of 18 mice having antibody concentrations less than 2.97 µg/ml. From
this, I conclude that non-rebounding mice did not have residual antibody levels
that would prevent rebound.
Since antibody levels decayed to the rebound threshold at different rates
within individual mice and the rebound threshold represents a population
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average, I calculated the number of days that elapsed from when each individual
mouse’s antibody levels reached the rebound threshold to when the mouse
actually showed rebound viremia. Fifty of 59 mice rebounded within 10 days,
indicating consistent timing of rebound kinetics (Fig. 19). In non-rebounding mice,
an average of 20.2 days elapsed from the time antibody concentrations reached
2.97 µg/ml to termination (Fig. 19). Thus, failure to rebound cannot be attributed
to premature termination. In total, I conclude that combining vorinostat, I-BET151
and αCTLA4 with combination antibodies decreases the frequency of viral
rebound in humanized mice.
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Figure 19. Persistent antibody levels at terminal point cannot explain lack
of viral rebound. (A) Antibody level at the time of rebound are shown for all
rebounding mice, divided by treatment group. Geometric mean of 2.97 µg/ml is
termed the rebound threshold (B) For rebounding mice, number of days that
elapsed from when each mouse’s antibody levels dropped beneath 2.97 µg/m to
when the mouse had rebound viremia (C) For non-rebounders, number of days
that elapsed from when each mouse’s antibody levels dropped beneath 2.97
µg/ml to when the mouse was sacrificed.
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2.7 ART and inducers

While the importance of combination inducers is evident from the 53 of 58
mice that rebound when not administered combination inducers, I sought to
determine if combination inducers in the presence of ART was equally efficacious
at preventing rebound, or if bNAbs played a unique role. I repeated the
experiments testing for viral rebound, except that viremia was suppressed using
ART (raltegravir, emtricitabine, tenofovir) rather than bNAbs. Of 9 mice that
survived the entire experiment, 6 showed viral rebound, a 67% rebound
frequency (Fig. 20). Although this is a higher rebound frequency than the 43%
observed for bNAbs plus combination inducers, it is statistically indistinguishable
due to limited numbers of mice (p = 0.43, Fisher’s Exact Test). To determine the
relative importance of bNAbs compared to ART, I adopted a different
experimental approach.
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Figure 20. ART plus combination inducers. Plasma viremias from mice
receiving ART plus combination inducers. ART administration shown in blue
shading, otherwise, coloring and shading as in figure 15.
2.8 bNAbs as post-exposure prophylaxis

Mice were exposed to HIV-1YU2 and treated with either ART or a tri-mix of
bNAbs 96 hours later, whether or not plasma viremia was detectable. Mice for
this experiment were selected with very stringent humanization criteria, and 14 of
15 untreated mice became viremic (Fig. 21). When non-humanized NRG mice
were exposed to identical amounts of HIV-1, virus was undetectable in the
plasma by 48 hours (Fig. 21). To estimate the total number of productively
infected cells within the spleen of a mouse just prior to therapy initiation, a
separate group of mice that had similar levels of human reconstitution were
exposed to HIV-1, then 96 hours later, plasma was collected and the mouse was
sacrificed. Plasma viremia was measured by qPCR, and the total number of
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human CD3+CD8-p24+ cells within each spleen was determined by flow
cytometry (Fig. 21).
In the experimental groups of mice receiving treatment, ART was
administered in the food for up to 40 days. Antibodies were administered
subcutaneously with an initial dose of 3 mg per mouse, and 3-5 subsequent
doses of 1.5 mg each, spaced 3-4 days apart, so that antibody levels were
maintained above 10 µg/ml for approximately 40 days (Fig. 21). Although plasma
viremia was suppressed beneath the detection limit in all 22 ART-treated mice
and cell-associated RNA was undetectable in 15 of 16 mice measured during
therapy, 18 mice showed rebound viremia after ART termination (Fig. 21). The
rebounding mice even included 5 mice that did not have detectable plasma
viremia before ART was initiated (measured ~90 hours following viral exposure).
Among the 18 viremic mice, viremia was first detected 28 to 84 days after ART
termination (Fig. 22). From this, I conclud that a pool of infected cells capable of
producing rebound viremia forms very early after exposure and persists
throughout therapy, indicating that ART is relatively ineffective at preventing
reservoir establishment in humanized mice when administered 4 days after
infection, consistent with human and macaque studies(Landovitz and Curry,
2009; Whitney et al., 2014).

49

B
HIV-1
challenge
Ab injections
days 0

5 10 15
ART
start
HIV-1
challenge

qPCR
45-120
qPCR

36
stop

106
105
104
103
102
102 103 104
total p24+ cells

D
Non-humanized mice

109

Untreated
Plasma Viremia

108
105
104
103

20

40

60

10 3

0

20

F

ART

Plasma Viremia

10

4

10 4

10 3

40

60

Days

80

100

Ab - Day 4

10 7

10 6
10

10 5

80

hours post infection

E

5

10 6

10 2

0

10 7

105

10 7

102

Plasma Viremia

107

101
101

C

Plasma Viremia

Plasma Viremia

A

p24+ cells vs viremia

1000

10 6
10

5

10

4

100
10
1

10 3
0.1

10 2

10 2
0

20

40

60

80

0

100 120

20

40

60

80

100 120

Figure 21. bNAbs and ART as PEP in humanized mice. (A) Experimental
schematic for post-exposure prophylaxis experiments (B) Absolute numbers of
human CD3+CD8-p24+ cells purified from the spleens of infected mice 4 days
after viral exposure (C) Clearance of cell-free plasma viremia in non-humanized
NRG mice. Red tick indicates copy number of virus stock injected i.p. (D) plasma
viremia in untreated mice. Geometric mean viremia shown in blue. (E) Plasma
viremia for mice treated with ART food. Gray lines indicate mice that become
viremic. Black lines indicate mice that do not become viremic by terminal point.
(F) Plasma viremia for bNAb-treated mice. Coloring as in figure 13.
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In contrast, only 10 of 21 (48%) mice treated with antibodies 4 days after
infection showed viremia by the terminal point, a statistically significant decrease
compared to ART (p = 0.027). For 9 of these 10 viremic mice, the first detectable
viremia occurred 74 or more days after the last antibody injection. The delay in
viral rebound observed for mice treated with antibody at day 4 was statistically
significant compared to ART-treated mice (Fig. 22). The mice that rebounded
showed a geometric mean antibody concentration at rebound of 0.46 µg/ml.
However, sustained inhibitory antibody levels did not account for the 11 mice that
did not rebound, all of which had antibody levels ≤0.50 µg/ml by termination (Fig.
23).
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Figure 22. Delay in viral rebound for bNAb-treated mice relative to ARTtreated mice. Survival curve showing the proportion of mice that are aviremic
over time following discontinuation of therapy. Blue arrow indicates
discontinuation of ART food.
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Mice in the early treatment group that failed to show detectable plasma
viremia were further examined for the presence of human CD4+ T cells and cellassociated HIV-1 RNA and DNA in the spleen. I found that mice that failed to
develop sustained plasma viremia had similar percentages of CD4+ T cells
relative to infected controls (Fig. 24). Therefore, differences in CD4+ T cell levels
are unlikely to account for the observed differences between viremic and
aviremic mice. Moreover, T cell-associated HIV-1 RNA levels were consistent
with plasma viral loads, with mice that remained aviremic having either
undetectable or lower cell-associated HIV-1 RNA than mice that developed
sustained viremia (Fig. 25A). HIV-1 DNA measurements were also consistent
with each mouse’s rebound status (Fig. 25B). I conclude that bNAbs can interfere
with the establishment of the HIV-1 reservoir in humanized mice as determined
by the significant delay in viral rebound.
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Figure 24. CD4+ T cell levels in the spleen do not differ across treatment
groups or viremia status. % human CD4+ T cells among human CD45+ cells as
measured by flow cytometry of splenocytes at the terminal point, grouped by
treatment and viremia status. Mice that never became viremic (A), closed circles.
Mice that became viremic (V), open circles. There is no statistical difference
across the groups (Kruskal-Wallis test).
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Figure 25. Cell-associated HIV-1 RNA and DNA in spleen of PEP mice. Cellassociated RNA (left) and DNA (right), expressed per cell equivalent, as
determined by CCR5 DNA copies. Gray shading shows beneath detection limit.
Circles and abbreviations as in figure 24.

To determine if bNAbs’ ability to prevent viral rebound could be improved
by initiating therapy earlier, I administered the same tri-mix of bNAbs 72 hours
after viral exposure. Only 2 of the 7 mice tested (29%) showed viremia by the
terminal point, when antibody levels were undetectable in the plasma (Fig. 26).
Although the observed rebound frequency was less than the 48% observed when
bNAbs were initiated 96 hours after exposure, there were too few mice to show a
significant difference. To see if bNAbs’ ability to prevent rebound viremia
extended beyond 3-4 days post-exposure, I administered the same tri-mix of
bNAbs 8 days after viral exposure. Ten of the 11 treated mice showed viral
rebound 44-58 days after the last antibody injection (Fig. 27). In total, the results
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show that bNAbs can interfere with the establishment of the viral reservoir, but
the efficacy is very time sensitive.
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Figure 26. Antibody PEP initiated at 72 hours following viral exposure. (A)
Plasma viremias for mice given a single injection of tri-mix bNAbs 72 hours after
viral exposure. Lines and coloring as in figure 21E. (B) HIV-1 copies per cell,
taken from the spleen at the terminal point. Open circles indicate mice that
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Figure 27. Antibody PEP initiated at day 8. Plasma viremias for mice initiated
with tri-mix bNAbs 8 days following viral exposure. Coloring and lines as in figure
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Because of the time sensitivity of therapy initiation and the different routes
of administration for bNAbs (subcutaneous injection) and ART (orally in food) in
these experiments, it was possible that the observed difference in the ARTtreated and bNAb-treated mice was due to different pharmacokinetics of the two
treatments. Specifically, the bNAbs were administered as a high-dose bolus
injection, whereas ART might have taken additional time to reach therapeutic
levels. However, measuring concentrations of anti-retroviral drugs in humanized
mice is difficult, so I used post-exposure prophylaxis treatments to indirectly
address this issue.
ART has been shown to be completely protective when administered
subcutaneously 24 hours after intravenous viral exposure and maintained for 28
days in macaques, but incompletely protective when initiated 48 hours after
exposure(Tsai et al., 1995; 1998). Thus any lack of protection when ART is
administered 24 hours after exposure via food suggests slower time to reach
therapeutic levels. Of 10 mice that were exposed to HIV-1 and given ART food
24 hours later for 30 days, all 10 remained aviremic for 92-131 days following
ART cessation (Fig. 28). There was no detectable cell-associated viral RNA in
the spleens of all mice tested (Fig. 28). From this, I conclude that ART
administered in the food within 24 hours of exposure can protect against viral
acquisition. By extension, the difference in efficacy of bNAbs and ART started at
4 days following exposure is not solely due to pharmacokinetics.
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Figure 28. ART as PEP within 24 hours. (A) Plasma viremias from mice
initiated on ART food 24 hours after viral exposure. (B) Cell-associated
HIV-1 RNA taken from splenocytes at the terminal point, expressed per
cell equivalent, as determined by CCR5 DNA copies. (C) absolute count of
total CD4+ T cells within the spleen at the terminal point.
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2.9 Importance of Fc Receptor Binding for bNAb Activity

Because pharmacokinetics could not entirely explain the observed
differences in preventing viremia between ART and bNAbs, I asked if bNAbs’
unique ability to engage components of the immune system through their Fc
domains played a role. I repeated the day 4 post-exposure prophylaxis
experiments using the same tri-mix of bNAbs, except the Fc region in each of the
component bNAbs carried mutations that abrogate both human and mouse Fcreceptor binding (G236R/L328R; GRLR, herein referred to as FcRnull(Horton et
al., 2010). Despite equivalent neutralizing activity in TZM-bl assays(Pietzsch et
al., 2012), FcRnull antibodies were far less potent than controls in vivo (Fig. 29).
Mice treated with FcRnull tri-mix initially suppressed viremia at the same rate as
the wild type antibody-treated mice. However 9 of 15 mice receiving post
exposure prophylaxis with the FcRnull tri-mix showed viral rebound by 44 days
after the last antibody injection. In contrast, 44 days after the last injection of
control antibodies, only 1 of 21 mice showed rebound viremia (p = 0.0004). Not
only was the delay in viral rebound significantly reduced for FcRnull antibodies,
but the antibody levels at the time of viral rebound were ~50-fold higher for mice
receiving FcRnull tri-mix compared to wild-type tri-mix (p = 0.0014, Fig. 29). This
suggests FcRnull antibodies have reduced activity in vivo, and thus Fc function
enhances antibody activity but is not an absolute requirement.
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Figure 29. FcRnull antibodies less effective than wild-type antibodies at day
4. (A) plasma viremias shown for mice treated with tri-mix of FcRnull antibodies
beginning 4 days after viral exposure. Coloring as in figure 21E. (B) Antibody
concentration at the time of viral rebound, shown by treatment group. *, p < 0.05,
**, p < 0.01, Mann-Whitney U Test (C) Proportion of mice that become viremic,
by treatment group. *, p < 0.05, Fisher’s exact test.
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Because mice receiving FcRnull tri-mix showed viral rebound in the
presence of antibody concentrations far higher than the therapeutic threshold for
wild-type antibodies, we cloned and sequenced gp120 from the 9 mice that
rebounded by day 44 to examine the mechanism for viral breakthrough in the
presence of FcRnull tri-mix (Fig. 30). As a control, gp120 clones from mice treated
with wild-type antibodies at day 8 were also sequenced. Among all 40 clones
sequenced from FcRnull tri-mix treated mice, not a single clone had the triple
combination of signature mutations that confer escape to the antibody-tri-mix. I
conclude that viral rebound in FcRnull tri-mix treated mice is not attributable to
antibody escape, but rather reduced antibody potency. Thus, FcRnull mutant
antibodies, which cannot engage Fc receptors, are less active in suppressing
infection than their wild type counterparts, and optimal post-exposure prophylaxis
by bNAbs requires engagement of Fc-receptors.
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Figure 30. Gp120 sequences of viral breakthrough clones show no
signature escapes. Gp120 sequences shown as in Figure 7.
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CHAPTER 3:
DISCUSSION

3.1 bNAb discovery

Prior to 2009, there were no known naturally occurring, potent, broadly
neutralizing antibodies against HIV-1. Advances in single cell cloning techniques
that allowed comprehensive probing of HIV-1-specific B-cells uncovered a “nextgeneration” of bNAbs with remarkable breadth and potency(Mouquet et al., 2012;
Scheid et al., 2011; Walker et al., 2009; 2011; Wilson and Andrews, 2012; Wu et
al., 2010). Although the best bNAbs come from rare patients that are carefully
selected, their discovery revealed the capacity of the human B-cell response to
target HIV-1 is far more impressive in some cases than previously recognized.
Additionally, structural, biochemical, and genetic characterization of bNAbs and
the viruses they neutralize revealed new sites of vulnerability on the virus. Most
importantly, these bNAbs provide a blueprint for a vaccine since passive transfer
of bNAbs prior to HIV-1 challenge can prevent viral acquisition(Hessell et al.,
2009; Mascola et al., 1999; Moldt et al., 2012; Shingai et al., 2013a).
However, within the patients whom these bNAbs come from, there has
been no definitive evidence showing bNAb-mediated viral control. In fact, these
patients appear to have circulating virus that is resistant to their own bNAbs(Wu
et al., 2012), likely owing to the kinetics of HIV-1 diversification and the B-cell
response. By the time the B-cell response can potently target HIV-1, the virus
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has already generated sufficient diversity to produce escape variants, giving rise
to a chase in which the virus is always a step ahead(Liao et al., 2013; Wei et al.,
2003). Because of the immense viral diversity and previous failed attempts to use
antibodies as therapeutic agents(Poignard et al., 1999; Trkola et al., 2005), the
therapeutic value of next-generation bNAbs was not immediately considered
following their discovery.

3.2 First demonstration of bNAb therapy

While the monoclonal antibodies ibalizumab and PRO140, which target
the human host receptors CD4 and CCR5, respectively, have been shown to
reduce viral loads in patients and may prove to be useful therapeutics, these
antibodies are not directly antiviral(Jacobson et al., 2009; 2010a; 2008; 2010b;
Kuritzkes et al., 2004). Our experiments demonstrated the efficacy of viralbinding bNAbs as therapy in vivo for the first time. Our data suggest that rapid
escape can occur to both single and double bNAbs, but combinations of three or
more bNAbs can fully suppress viremia. The most striking aspect of these
experiments was the restricted escape routes observed in the virus for single or
double bNAb-therapy. While previous analyses of antibody-mediated escape
found a wide-range of viral escape options, often involving addition and removal
of N-linked glycosylation sites across many residues in gp120(Frost et al., 2005;
Wei et al., 2003), I found that escapes to the bNAbs tested were limited to just 13 sites shared across multiple mice. For 10-1074, the restriction was particularly
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impressive, with only a single amino acid substitution at a single residue
dominating the viral quasi-species. An important caveat is that humanized mice
in our experiments were infected with monoclonal HIV-1YU2, a clade B primary
isolate, and viral escape routes with other virus strains should be tested to be
more comprehensive.
Our data suggest that the in vivo success of the next-generation bNAbs
we tested compared to the failures of previous antibodies tested is attributable to
the exceptional potencies and restricted escapes. The geometric mean inhibitory
concentration to block 50% infection (IC50) as tested by in vitro TZM.bl assays of
the four efficacious bNAbs is 0.07 µg/ml, whereas it is ~1.5 logs lower at 2.63
µg/ml for 2G12, 2F5 and b12—the 3 antibodies tested in a humanized mouse
system previously. The lone “next-generation” antibody we tested that did not
have any therapeutic effect in vivo, 3BC176, has an IC50 resembling the
ineffective antibodies at 1.87 µg/ml. Additionally, 10-1074, the antibody that
produced the largest transient drop in viremia of 1.5 logs had the most restricted
in vivo escapes detected.
Despite the transient drops in viral load and emergence of limited escape
mutations, there was no evidence of a fitness cost imposed by these mutations.
The viral loads quickly returned to pre-therapy levels, and the virus maintained
the mutations even when therapy was stopped. Additionally, the escape
mutations to the various antibodies did not appear incompatible in any way when
they were all present in the same virus. Rather, the escape mutations we saw in
single-bNAb treated mice were the same as those seen in mice that escaped

63

from a combination of two efficacious bNAbs. Additionally, a virus engineered to
contain escapes to all four of the efficacious bNAbs we tested was shown to be
highly infectious in humanized mice. Together, this shows that escape to bNAbs
is additive. Furthermore, it is possible that pre-existing viral clones within a
patient’s quasi-species contain escapes to all bNAbs in a cocktail, in which case
the cocktail will be ineffective. This issue can likely be overcome by choosing
bNAb cocktails that have rare, restricted escapes unlikely to be present within the
same virus simultaneously by pre-screening patients and databases of viruses
within the population. In all, these studies demonstrated sufficiently broad and
potent bNAbs could lead to sustained viral suppression in vivo for the first time.

3.3 Antibodies as PEP

Because antibodies have the potential for Fc-mediated cell killing while
ART can only block new rounds of replication, I employed a post-exposure
prophylaxis model to test the role of cell killing. By comparing the PEP efficacy of
antibodies versus ART, I can infer therapeutic roles that extend beyond blocking
new rounds of replication. I found that cell-free virus injected intraperitoneally into
non-humanized NRG mice is undetectable in plasma by 48 hours. Thus plasma
viremia detectable after 48 hours in humanized mice must come from
productively infected cells. If therapy is initiated 48-96 hours after exposure, and
assuming therapy completely blocks viral spread, it can be inferred that viral
rebound occurring after therapy cessation comes from the earliest infected cells.
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Conversely, if there is no viral rebound upon therapy cessation, then either the
early-infected cells were cleared, or they remained in a silent state without virus
production. While this experimental setup requires many assumptions to
indirectly conclude that antibodies kill infected cells, there is no alternative model
to prove this in vivo. This is complicated by the fact that productively infected
cells die very quickly, so any role for antibody-mediated killing is likely to be
supplemental.
Nevertheless, my experiments show that bNAbs were significantly more
effective than ART at preventing viral rebound in the PEP model. However, the
enhanced efficacy of bNAbs is abrogated when their ability to bind Fc receptors
is removed. Identifying which Fc-expressing cells are most important for Fcmediated effects of bNAbs remains an open question. It is particularly difficult to
address in the humanized mouse model because of the incomplete human
reconstitution. While bNAbs were administered by subcutaneous injection and
ART was administered orally in the food, the difference in efficacy between
antibodies and drugs is unlikely to be solely due to pharmacokinetics. When
orally administered ART was initiated at 24 hours following viral exposure, no
mice showed viremia by the terminal point, in agreement with results in
NHPs(Tsai et al., 1995). In NHPs, low-potency neutralizing IgG was tested for
PEP and shown to be effective only when initiated within 6 hours(Nishimura et
al., 2003). The extended window of opportunity for next-generation bNAbs needs
to be tested in the NHP model, but the results suggest a role for enhanced killing
or viral containment with bNAbs. If bNAbs as PEP show similar beneficial effects
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in NHPs, there is a strong case to include them in early treatment regimens.
Additionally, they can be added to ART as a superior PEP for occupational
exposures.

3.4 Model for Latency Purging Regimens

The possibility of antibody-mediated killing stimulated me to test the
effects of bNAbs in clearing latent cells. However, there is no established small
animal model to test this. From our experiments testing bNAbs as therapy, I
noticed the majority of mice that were suppressed showed viral rebound when
antibody levels dropped beneath the therapeutic threshold. There were no
signature escape mutations contained within the rebounding virus, and it
remained sensitive to antibody neutralization, implying the persistence of a silent
pool of infected cells capable of producing viral rebound. By purifying resting
CD4+ T cells from suppressed mice and detecting HIV p24+ in the supernatant
following culture in T-cell stimulatory conditions, I was able to confirm the
existence of replication-competent virus within this cell subset. Although I have
not proven that this cell subset is responsible for the rebounding virus observed
in humanized mice, I demonstrated that it exists, in agreement with findings from
bone marrow-liver-thymus (BLT) humanized mice(Denton et al., 2012; Marsden
et al., 2012). Given that resting memory CD4+ T cells with replication-competent
provirus are regarded as the biggest barriers to reservoir eradication, the model
gave me the opportunity to study viral purging strategies in vivo.
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I carefully designed our viral purging experiments to work within the
constraints of the humanized mouse model. Because the duration of the human
graft is variable and limiting, I planned the entire course of treatment to fit within 4
months, a time frame well within the empirically determined graft duration of the
model. I suppressed viremia in mice, administered the experimental therapies,
then stopped therapy and assayed for viral rebound in the plasma. I used viral
rebound since it is considered the gold standard for evaluating viral eradication
strategies. Additionally, it has an easy to interpret binary outcome, represents the
most important clinical parameter, and avoids the problems associated with
reservoir size measurements.

3.4.1 Limitations of the model
Despite the unique experimental opportunities provided by the humanized
mouse model, using it for viral purging strategies comes with many caveats. The
main caveats related to the experiments discussed are: (1) incomplete
reconstitution of human cells, (2) lack of proper lymph node architecture (3)
limited duration of the human graft, (4) significantly reduced absolute cell
numbers, and (5) non-physiological environment of mixed human and mouse
cells.
The incomplete human reconstitution manifests as a very narrow range of
human immune cells populating each mouse. Although, mice that have clear
populations of human CD4+ T cells are selectively chosen for the experiments, it
has never been verified that these CD4+ T cells are capable of differentiating into
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the full range of CD4+ T cell subtypes. Additionally, there are very few innate
immune human cells in these mice, such as macrophages, and natural killer
cells(Brehm et al., 2010). Considering some of these innate cells have been
implicated as being susceptible to HIV infection, and may contribute to the HIV
reservoir in some cases, humanized mice have a significantly reduced pool of
cells capable of forming the reservoir. Therefore it must be tested whether
targeting strategies that eliminate reservoirs in humanized mice translate to the
more diverse, complex reservoirs in humans.
The humanized mice used in these experiments also lack proper lymph
node architecture, as well as lymphoid tissues that are relevant for HIV infection,
such as gut associated lymphoid tissue (GALT) and mucosa associated
lymhphoid tissue (MALT) (Li et al., 2005; Moir et al., 2011). Given the high levels
of viral replication and relatively high frequencies of HIV-infected cells in these
tissues, the absence of these tissues from hu-mice may make the bar to purging
virus far lower than in animal models that have these features.
The limited duration of the human graft poses one of the greatest caveats
to the model. Following infection, plasma viremia is stable for ~3-6 months in
humanized mice, with gradual depletion of CD4+ T cells(Baenziger et al., 2006).
Eventually, the human graft’s proliferative capacity cannot keep pace with cell
loss, and both human immune cells and plasma virus become undetectable—
limiting the study duration of HIV therapeutics. In clinical trials of latency purging
strategies, patients who receive the experimental intervention have usually been
chronically infected with HIV for many years then suppressed on ART drugs for 6
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months or longer. The purpose of this minimal suppression time is usually
attributed to the presence of labile, unintegrated forms of HIV that are able to
persist in the presence of ART for up to 6 months(Blankson et al., 2000).
However, these more labile forms of HIV are not believed to represent the stable
reservoir and so they are excluded from tests of purging efficacy. It is not
possible to use the same stringent time constraints in tests with humanized mice.
Rather, mice are suppressed following just weeks of infection—a time frame
considered acute for humans—and the experimental intervention is initiated after
just weeks of suppression. As a result, it is unknown if clearance of latent
reservoirs in mice will translate to clearance of human latent reservoirs.
Additionally, many latency purging pharmacologic regimens tested in
clinical trials use multiple weekly drug cycles extending over many months(Archin
et al., 2014; MD et al., 2014). It is believed that a single short-course
administration of latency reversal agents is not sufficient to reactivate enough of
the silent reservoir to make a difference. However, it is not possible to test
multiple cycles of treatment in mice because the total experimental window is too
short.
The total number of human CD4+ T cells within each humanized mouse is
orders of magnitude less than in a human. While I demonstrated that the
frequency of latently infected resting CD4+ T cells is comparable to that seen in
humans, the total number of latently infected cells is likely orders of magnitude
less. Given the total number of ~1 to 10 million human CD4+ T cells in each
mouse—and on the order of 104 p24+ cells during active infection—there are
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likely only 1-10 latently infected resting CD4+ T cells within each mouse. This is
in contrast to the 104-107 estimated latently infected resting CD4+ T cells that
exist in an infected human(Chun et al., 1997a; Zhang et al., 1999a). While the
precise number of latently infected cells that can remain without causing
virological relapse is unknown, it is generally appreciated that even very few
numbers of latently infected cells can lead to virological relapse(Henrich et al.,
2014). As a result, the very few numbers of latently infected cells within a
humanized mouse make the possibility of viral eradication significantly easier.
The environment of mixed mouse and human cells that are free to interact
within the humanized mouse model is another potential shortcoming for studying
latency in the humanized mouse model. The main concern is that mouse cells
provide continual allogeneic stimulation to the human immune cells, which
precludes a true resting state. Considering that HIV latency is most stable within
resting CD4+ T cells that do not express activation markers such as CD25, CD69,
or HLA-DR, the mixing of mouse and human cells may make the environment
significantly different from that which latent cells in a human are exposed to.
However, this concern remains speculative and there has been no clear
evidence suggesting that human cells cannot exist within a resting state within an
NRG mouse. To the contrary, I was able to identify resting CD4+ T cells that were
CD25-CD69-HLA-DR-. However, additional comparisons between silent,
persistently infected cells from humanized mice and latently infected human
CD4+ T cells, such as integration site analyses and gene expression analyses
will have to be done to address this issue directly.
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3.5 Importance of combinations for latency reversal

Although combination antibody therapy appeared to work similarly to ART
in that triple combinations were required, the unique potential for Fc-mediated
effects that can directly kill infected cells led me to test the “shock and kill”
approach. I tested three candidate inducers of viral transcription (aka LRAs)
based on their abilities to reverse latency in vitro, target different mechanisms of
transcriptional silencing, and toxicities. I found that combining a bNAb cocktail
that could suppress viremia with a single inducer had no impact on the frequency
of viral rebound in humanized mice. However, a combination of all three inducers
significantly reduced the frequency of viral rebound. This is the first
demonstration of a therapy regimen other than irradiation and stem cell
transplant with HIV-resistant donor cells that reduced viral rebound in vivo.
This study demonstrates that current LRAs are unlikely to have a
significant impact on the latent reservoir when administered as single agents.
This is supported by studies investigating vorinostat and panobinostat as single
agents(Archin et al., 2014; Elliott et al., 2014; MD et al., 2014). It suggests that
future studies should focus on optimizing the best inducer combinations, rather
than relying on single agents. Of note, I did not optimize my inducer regimen, and
~40% of treated mice still showed viral rebound, underscoring room for
improvement. However, I attribute the improved success of the LRA combination
to synergy in targeting different mechanisms of reactivation. This is likely related
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to the multiple mechanisms regulating HIV transcriptional silencing. No single
agent is likely to target all these mechanisms, so there is probably a population of
unperturbed latent cells capable of producing rebound viremia when single
agents are used. This is supported by in vitro findings that show a very small
fraction of proviruses are activated by single LRAs(Cillo et al., 2014).
Additionally, single agents may induce viral transcription, but there is no evidence
that single agents robustly reverse latency to induce viral protein expression,
which is likely required for immune-mediated killing.

3.6 Testing for latency reversal

Rather than testing for cell-associated viral RNA, the more relevant test is
for viral protein expression, including cell surface-HIV Env, in reactivated cells.
Not only do broad, potent bNAbs exhibit clinical promise, but they can be used in
the laboratory as agents to identify infected cells expressing surface Env. This
has the potential to offer a more relevant assay for detecting cells that were
reactivated sufficiently for bNAb-mediated killing.
Although I tested for changes in cell-associated viral RNA during the
inducers treatment, I was unable to detect any in both the single inducers treated
mice and combination-inducers treated mice. While this differs from the ~3-5 fold
increases observed in vorinostat and panobinostat trials(Archin et al., 2012;
Elliott et al., 2014; MD et al., 2014), it could simply be due to a lower sensitivity in
this model due to fewer cells assayed. But more importantly, the lack of cell-
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associated RNA detection did not predict lack of viral rebound, which suggests
an updated readout should be used for clinical trials that test latency reversal. In
total, my experiments make clear that current LRA strategies are likely limited by
incomplete reactivation and major effort should go toward improving this, as well
as assays to detect reactivated cells that can be killed.
Given the challenges in improving latency reversal and infected-cell killing,
it is critical to have an in vivo model amenable to testing many strategies. Prior to
this work, only in vitro models consisting of transformed cell lines or PBMCs
isolated from ART-suppressed patients existed for testing “shock and kill”
strategies pre-clinically. While these models allow high-throughput screening,
they lose physiologic relevance. Prior to this work, LRAs could not even be
tested in NHPs because there were no fully-suppressive ART regimens
available. This issue has now been resolved, but there are still significant
advantages of using humanized mice.
For one, humanized mice involve HIV infection of human cells. In contrast,
restriction factors limit the tropism of HIV, so NHPs have to be infected with
either simian immunodeficiency virus (SIV) or an SIV/HIV hybrid virus termed
SHIV. It is unclear how SIV or SHIV viruses differ from HIV for latency and
eradication strategies and it is unclear how LRAs will interact with simian cells
since LRAs are generally discovered based on activity in human cells.
Additionally, humanized mice are less costly and more high-throughput than
NHPs.
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However, humanized mice also have some disadvantages. For one, they
are immune-compromised so it is difficult to study the role of the immune system
in viral clearance and eradication. NHPs offer the advantage of a fully competent
immune system. Also, studies of latency in humanized mice are limited by human
graft duration and composition. Most studies of candidate LRAs in humans
involve patients who are suppressed on ART for >6 months to avoid effects from
labile forms of unintegrated HIV. This is not possible in humanized mice unless
an alternative approach is adopted. To further the model for latency testing, it will
be important to characterize the forms of integrated and unintegrated forms of
HIV in humanized mice and compare them to ART-suppressed patients. The
limited graft duration also limits the duration of reactivation treatment that can be
tested, making it impossible to optimize dosing schedules.
Nevertheless, I established an in vivo system to test LRAs in conjunction
with both ART and antibodies. I was also able to test Fc-mediated effects by
manipulating the Fc region of the antibody. However, my studies come with the
caveat that innate human immune cells expressing Fc receptors, such as
monocytes and Natural Killer cells, are rare in my model so it is impossible to
assess the full extent of Fc-FcR interactions. I believe that improved humanized
mouse systems that partially restore innate immune function will further our
understanding of Fc-FcR mediated effects on infected cells in vivo(Rongvaux et
al., 2014).
However, the duration of the human graft is reported to be much shorter
than 4 months in these improved humanized mouse systems, so they seem more
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amenable to studying short-term cell-killing. Alternatively, an adapted model for
studying LRAs and antibodies could be used in these mice by adoptively
transferring resting memory CD4+ T cells known to harbor integrated provirus,
either from patients or other mice. This eliminates the first two months where the
mouse is infected then suppressed, allowing the experimental regimen to be
administered and viral rebound to be monitored within the duration of the human
graft. Additionally, this approach could be adopted in our current humanized
NRG mouse model to allow time for multiple rounds of LRA administration. In my
recent studies, multiple rounds were not permitted within the experimental time
frame.

3.7 Translation to humans

Ultimately though, the concepts and most promising treatment regimens
need to be tested in humans. Traditionally, the pipeline to reach human clinical
trials involves testing in the NHP model. During the course of this work, passive
antibody therapy was shown to be effective at sustainably suppressing viral loads
in NHPs(Barouch et al., 2013; Shingai et al., 2013b).
While rapid escape to single bNAbs may occur, it remains unclear what
combinations of bNAbs will be required to suppress viremia in an immune
competent individual that can mount both B-cell and T-cell responses. The viral
diversity within patients, as well as the immune responses mounted by patients
are both likely to be important variables. Evidence from NHPs suggest that a
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single bNAb is sufficient in some cases, and work in humanized mice suggests
this is because of endogenously produced V3-loop antibodies that complement
the passively administered bNAb to prevent escape(Klein et al., 2014).
Alternatively, we showed that reducing viral loads in humanized mice with
ART prior to bNAb administration—presumably reducing viral diversity as well—
enabled a single bNAb to sustainably suppress viremia without escape(Horwitz
et al., 2013). In light of our results in mice, and the extension to NHPs, bNAb
therapy has progressed to clinical trials (clinicaltrials.gov NCT02018510,
NCT02165267, and NCT02256631). While these first studies are testing safety,
pharmacokinetics, and therapeutic efficacy of monocloncal antibodies in humans,
I expect my data demonstrating the ability of bNAbs to interfere with reservoir
establishment and maintenance in humanized mice will inspire additional human
studies examining the impact on the latent reservoir.
Human studies of LRAs combined with antibodies are also likely to
advance to clinical trials in light of my work. However, the “shock and kill”
approach requires many more advances until it carries the same promise that
bNAb-therapy possesses. For one, LRA combinations and a dosing schedule
should be optimized. Both of these remain major questions in the field. LRAs
have predominantly focused on HDAC inhibitors, and it is likely that other
candidate LRAs will be needed to reverse latency more robustly.
Regardless of the findings from the initial clinical trials, it is important to
note that there are many potential improvements for bNAbs. One, half-life can be
significantly increased with select mutations in the Fc region that impact binding

76

to Fc neonatal receptor (FcRn) and endosomal recycling(Ko et al., 2014). Two,
bNAbs can be engineered to have different Fc-mediated properties depending on
the relative affinities for various Fc receptors. And three, bNAbs can be rationally
designed to enhance breadth and/or potency(Diskin et al., 2011). Ultimately, the
studies conducted and reported here offer promise for the future of bNAbs in
treating HIV-1, but many important advances are required to achieve the very
difficult goal of viral eradication.
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CHAPTER 4:
METHODS
4.1 Humanized Mice

4.1.1 Mice.
NOD Rag1-/-Il2rgNULL (NOD.Cg-Rag1tm1Mom Il2rgtm1Wjl/SzJ, NRG) mice were
purchased from The Jackson Laboratory. All mice were and bred and maintained
at the Comparative Bioscience Center of The Rockefeller University according to
guidelines established by the Institutional Animal Committee. All experiments
were performed with authorization from the Institutional Review Board and the
IACUC at The Rockefeller University.

4.1.2 Hematopoietic Stem Cell Purifications.
Human fetal livers (gestational age 16-22 weeks) were obtained from Advanced
Bioscience Resources (ABR). Fetal livers were homogenized and incubated in
Hank’s Balanced Salt Solution (HBSS) media with 0.1% collagenase IV (SigmaAldrich), 40 mM HEPES, 2 mM CaCl2 and 2 U ml-1 DNAase I (Roche) for 30
minutes at 37° C. Human CD34+ HSCs were isolated from digested liver using
CD34+ HSC isolation kit (Stem Cell Technologies) according to manufacturere’s
protocol. Neonatal NRG mice (1-5 days old) were sublethally irradiated with 100400 cGy and injected intrahepatically with 2✕105 human CD34+ HSCs 6 hours
after irradiation.
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4.1.3 Humanized Mouse screening.
Eight or more weeks after HSC injection, mice were screened for the presence of
human lymphocytes in peripheral blood by flow cytometry. 200 µl whole blood
was collected by facial vein bleed and peripheral blood mononuclear cells
(PBMCs) were isolated by density gradient centrifugation using Ficoll-Paque Plus
(GE Healthcare Life Sciences). PBMCs were stained with antibodies to mouse
CD45-PECy7, human CD45-Pacific Orange, human CD3-Pacific Blue, human
CD19-APC, human CD4-PE, human CD8-FITC, and human CD16-Alexa700 for
25 min at 4°C. Cells were washed and fixed using Cytofix/Cytoperm (BD
Biosciences). Flow cytometry analysis was performed with a LSRFortessa (BD)
and FlowJo software (Tree Star). For each mouse, the percentage of human
lymphocytes [(100 x human CD45+) / (human CD45+ + mouse CD45+)], termed
huCD45+ %, and the percentage of human CD4+ T cells (100 x human
CD45+CD3+CD4+ / human CD45+), termed huCD4+ %, was calculated. Mice with
at least 10% huCD45+ and 10% huCD4+ were selected for post-exposure
prophylaxis experiments, and infected with two doses of HIV-1YU2 (150 ng p24)
by i.p. injections, 24 hours apart. Pre-treatment viremia was measured at 72-96
hours following the first HIV-1YU2 injection, and treatment was initiated 4 days
following the first injection. For experiments assessing the effects of bNAbs and
inducers on established infections, mice with measurable human CD4+ cells by
FACS were injected with two doses of HIV-1YU2 (150 ng p24), and pre-treatment
viremia was measured 14-18 days after the first injection. Mice with plasma viral
loads >3000 RNA copies/ml were selected to receive antibody therapy. After five
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subcutaneous antibody injections (see below), post-treatment viremias were
measured. Only mice with completely suppressed plasma viremias were selected
for further analysis and to receive viral inducers.

4.2 HIV-1YU2 virus production

HIV-1YU2 used for mouse infections was produced in 293T cells. 25 µg plasmid
was mixed into 1.3 ml Opti-MEM (Life Technologies) and 75 µl Xtreme Gene 9
(Roche) was added to form DNA mixture. DNA mixture was then added dropwise
to 293T cells in reduced serum media (RPMI plus 3% Fetal calf serum). Media
was replaced 6 hours later with reduced serum media. Viral supernatant was
harvested at 24 hours and 48 hours after transfection. Supernatant was passed
through 0.22 µm filter and viral concentration was measured by p24 AlphaLISA
(PerkinElmer) according to manufacturer’s instructions.

4.3 Generation of HIV-1YU2 envelope mutants

Single, double and triple mutations were introduced into wild-type HIV-1YU2
envelope by site-directed mutagenesis using the QuikChange site-directed
mutagenesis kit (Agilent Technologies) according to the manufacturer’s
specifications.
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4.4 Plasma viral load measurements

300-500 µl of whole blood was collected from mice at each time point by facial
vein bleed. Whole blood was spun at 300g for 10 minutes to separate plasma
from the cellular fraction. Total RNA was extracted from 100 µl plasma using
QIAmp MinElute Virus Spin Kit (Qiagen) in combination with RNase-free DNase
(Qiagen), eluted in a 50 µl volume. HIV-1 RNA was quantified by qRT-PCR. The
reaction mixture was prepared using TaqMan RNA-to-Ct 1-Step kit (Applied
Biosystems), with 20 µl of eluted RNA, and a sequence specific probe targeting a
conserved region of the HIV-1 pol gene (/HEX/5’CCCACCAACARGCRGCCTTAACTG-3’/ZenDQ, HXB2 nt 4603 to 4626)
(Integrated DNA Technologies). Forward and reverse primer sequences were 5’TAATGGCAGCAATTTCACCA-3’ (HXB2 nt 4577-4596) and 5’GAATGCCAAATTCCTGCTTGA-3’ (HXB2 nt 4633 to 4653), respectively.
Reaction mixtures included 450 nM forward and reverse primers and 125 nM
probe. Cycle threshold (Ct) values were calibrated using standard samples with
known amounts of absolute viral RNA copies. The quantitation limit was
determined to be 800 copies/ml.

4.5 Cell-associated HIV-1 RNA

The cellular fraction of whole blood was resuspended in 400 µl PBS and PBMCs
were isolated by density gradient centrifugation as described above.
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Lymphocytes were split into two samples, one for cell-associated HIV-1 RNA
measurements, and one for cell-associated HIV-1 DNA measurements. Cellassociated RNA was extracted and quantified by the same procedures as
described above for plasma viral RNA. The lower limit of detection was
determined to be 10 copies viral RNA per qRT-PCR reaction. Cell-associated
HIV-1 RNA is reported as the ratio of HIV-1 RNA copies per sample to CCR5
genomic DNA copies per equivalent sample measured in DNA extract. For
terminal point measurements, spleen tissue was isolated, homogenized, and
filtered through 40 µm mesh. Splenocytes were used to isolate HIV-1 RNA as
described above.

4.6 Cell-associated HIV-1 DNA

PBMCs were isolated from whole blood as described above. Splenocytes were
isolated from spleen as described above. Total DNA was extracted using QIAmp
DNA Blood Mini Kit (Qiagen) and eluted in 80 µl volume. Purified DNA was
quantified for HIV-1 DNA by qPCR using the primers and probe for HIV-1 RNA
quantification mentioned above. Genomic human CCR5 DNA was quantified with
primers 5’-GTTGGACCAAGCTATGCAGGT-3’ (forward) and 5’AGAAGCGTTTGGCAATGTGC-3’ (reverse), and the sequence-specific probe
/HEX/5’-TTGGGATGACGCACTGCTGCATCAACCCCA-3’/ZenDQ. All qPCR
reactions contained 25 µl AmpliTaq Gold PCR master mix (Applied Biosystems),
in 50 µl reaction volume. Reaction mixtures were 150 nM forward and reverse
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primers with 41.5 nM CCR5 probe. HIV-1 DNA is reported as copies per sample
to CCR5 genomic copies per equivalent sample.

4.7 Gp120 Sequencing

4.7.1 Gp120 cloning
All PCR amplifications were performed in ThermoGrid 96-well plates (Denville
Scientific). cDNA was synthesized from viral RNA using SuperScript III reverse
transcriptase (Invitrogen Life Technologies). cDNA was amplified with either
Expand High Fidelity PCR System (Roche) or Clontech Advantage 2 PCR
System (BD). Primers for the first round of PCR were 5’GGCTTAGGCATCTCCTATGGCAGGAAGAA-3’ and 5’GGTGTGTAGTTCTGCCAATCAGGGAAGWAGCCTTGTG-3’. Primers for the
second round of PCR were 5’-TAGAAAGAGCAGAAGACAGTGGCAATGA-3’
and 5’-TCATCAATGGTGGTGATGATGATGTTTTTCTCTCTGCACCACTCTTCT3’.
Cycling parameters for first round PCR were 94° C for 2 min followed by
40 cycles of 94° C for 30 s, annealing temperature of 55–65° C for 45 s, 68° C for
4 min, and a final extension at 68° C for 10 min, where the annealing
temperature was 65° C for the first 3 cycles, 60° C for the next 11 cycles, and 55°
C for the final 26 cycles. 3 ml of product from the first round was used as the
template for the second round of PCR. Cycling conditions for the second round
PCR were 94° C for 2 min followed by 40 cycles of 94° C for 30 s, annealing

83

temperature of 53–55° C for 45 s, 68° C for 2 min and 30 s, and a final extension
at 68° C for 10 min, where annealing temperature was 53° C for the first 9 cycles
and 55° C for the next 31 cycles. After the second-round PCR amplification, 0.5
µl Taq polymerase was added to each 50 µl reaction and an additional 72° C
extension for 15 min was performed to add 3’ A overhangs for use in cloning.
Gel-purified PCR amplicons were ligated into pCR4-TOPO (Invitrogen) and
transformed into One Shot TOP10 cells. Individual colonies were sequenced
using M13F and M13R primers.

4.7.2 Sequence alignments and mutation analysis
Forward and reverse sequence reads from individual samples were assembled
using Geneious Pro software version 5.5.6 (Biomatters Ltd) and aligned to gp120
YU2

(accession number M93258). Env sequences containing frameshift mutations

or large deletions were excluded from further analysis. All sequences were
analyzed for mutations relative to gp120 YU2 using the Los Alamos Highlighter
tool (http://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/HIGHLIGHT_XYPLOT/highlighter.html), and
mutations were numbered using HXBc2 numbering as determined by the Los
Alamos Sequence Locator tool (http://www.hiv.lanl.gov/content/sequence/
LOCATE/locate.html)
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4.8 Terminal Graft

The presence of human lymphocytes at the terminal point was quantified from
the spleen and PBMCs by flow cytometry. Isolation of PBMCs and splenocytes
were as described above. Staining procedures were the same as described for
humanized mice screening.

4.9 Measuring Antibody Levels

Plasma levels of passively administered antibodies were quantified by two
independent methods. The first method was gp120 specific ELISA. Costar 96Well EIA/RIA Stripwell plates were coated overnight with gp120YU2 protein at 50
µg/ml, in 50 µl volume per well. Plates were washed 3✕ with distilled water plus
0.05% Tween and blocked for 2 h with PBS containing 0.1% Tween-20, 2%
Bovine Serum Albumin and 1 mM EDTA. After washing the plate, mouse plasma
was applied in 1:3 serial dilutions with a 1:20 starting dilution. 3BNC117 and 101074 of known concentration were used as standard antibodies for each plate to
quantify gp120-specific IgGs. Starting concentration of 3BNC117 and 10-1074
standards were 12 µg/ml, and diluted in 1:3 serial dilutions identical to the serum
samples. The plate was then incubated for 1 h at 37° C, followed by washing the
plate and 1 h incubation with peroxidase-conjugated goat anti-human IgG
(Jackson ImmunoResearch), 1:1000 dilution, 50 µl per well. Plates were washed
and developed using ABTS single solution (Invitrogen). Optical density was
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measured at 405 nm and IgG concentration determined by correlation to the
standard curve of the reference antibodies. The detection limit was 0.05 µg/ml.
Because PG16 does not bind gp120, and endogenously produced gp120reactive antibodies could confound the ELISA measurement, plasma antibody
levels were also quantified by TZM-bl neutralization using the Tier 2 envelopes
3301.v1.c24 and YU2. Because we have never observed Tier 2 neutralizing
activity endogenously produced from a humanized mouse, this measurement is
more stringent for detecting the passively administered antibodies. Mouse
plasma samples were serially diluted 1:5 down to a final dilution of 1:~4✕106,
starting at 1:50 dilution. Each dilution was tested on TZM.bl assay for
neutralization of the pseudoviruses mentioned above to give an IC50 neutralizing
titer. A mixture with known amounts of 3BNC117, 10-1074, and PG16 was used
as standard. The IC50 neutralizing titer of the serum samples was compared to
the IC50 concentrations of the antibody standard mix to determine antibody
concentrations from the serum samples.

4.10 Day of viral rebound and antibody level at rebound

Plasma viremias immediately preceding and following viral rebound were plotted
on a semi-log-y-axis versus days post initial antibody injection (x-axis) for each
individual mouse. The linear portion of viremia was fit to a line by least-squares
linear regression. The day that viremia crossed the 800 copies/ml quantitation
limit, termed rebound day, was calculated from the viremia fit. The antibody
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concentrations (as determined by TZM-bl neutralization) spanning before and
after viral rebound were plotted on a semi-log-y-axis versus days post initial
antibody injection. The linear portion of antibody concentrations was fit to a line
by least-squares linear regression, and the antibody concentration on the
rebound day was calculated from the fit.

4.11 Anti-retroviral therapy

Individual tablets of tenofovir disproxil-fumarate (TDF; Gilead Sciences),
emtricitabine (FTC; Gilead Sciences), and raltegravir (RAL; Merck) were crushed
into fine powder and manufactured with TestDiet 5B1Q feed (Modified LabDiet
5058 with 0.12% amoxicillin) into ½” irradiated pellets. Final concentrations of
ART drugs in the food were 720 mg/kg TFV, 520 mg/kg FTC, and 4800 mg/kg
RAL. Doses were chosen based on suppression of viremia in humanized mice as
previously published(Denton et al., 2012; Nischang et al., 2012), and by
pharmacokinetic analysis of these drugs in humanized mice (unpublished, Speck
Laboratory). To test potential toxicity, or reduced preference for drugsupplemented food, mice were weighed daily on normal diet, then switched to
ART feed and weighed daily. There were no visible signs of toxicity and mice
maintained their weights. On average, each mouse consumed 4.7 g of food per
day, consistent with reports for typical mouse consumption.
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4.12 Antibody therapy

Plasmids encoding 10-1074 or PG16 heavy- and light- chain Ig genes were
transfected into HEK 293E cells. Antibodies were isolated from tissue-culture
supernatant using Protein G Sepharose 4 Fast-Flow (GE Healthcare). Antibodies
were then buffer-exchanged into PBS and sterile-filtered using Ultrafree-CL
centrifugal filters (0.22µm; Millipore). Endotoxin was removed from antibody
preparations using Triton X-114 (Sigma-Aldrich). Antibody suspensions were
mixed with 10% Triton-X114 in a 15 ml falcon tube, vortexed, placed on ice for 15
min, vortexed again, placed in 42° C water bath for 15 min, then centrifuged at
3000 rpm for 5 minutes without brake. The top phase containing the endotoxinremoved antibody was kept and concentrated to 10 mg/ml. Sterile, endotoxinfree 3BNC117 (20 mg/ml) was obtained from CellDex Therapeutics. All
antibodies were injected subcutaneously as described.

4.13 Inducers

Vorinostat (Selleckchem) was suspended in sterile water or sterile water plus
0.5% methylcellulose, 0.1% Tween (v/v) and administered by oral gavage at
doses of 60 mg/kg. For each mouse, three total doses were administered,
spaced 48 hours apart. 100 µg doses of αCTLA4 were injected intraperitoneally
(i.p.). Three total doses were administered, spaced 48 hours apart. I-BET151
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was obtained from GlaxoSmithKline and dissolved in 10% beta-cyclodextrin, 5%
DMSO in 0.9% saline and injected daily for 14 days at doses of 30 mg/kg.

4.14 Viral outgrowth assay

Mice were sacrificed and spleen and lymph nodes were homogenized into single
cell suspension through 40 µm filter. To isolate resting human CD4+ T cells for
culture, a three-step process was used. First, mouse cells were depleted using
the Mouse Cell Depletion Kit (Miltenyi) according to manufacturer’s instructions.
Second, human CD4+ T cells were enriched by negative selection using human
CD4+ T cell isolation kit (Miltenyi). Third, activated CD4+ T cells were depleted
using CD69, HLA-DR, and CD25 microbeads, leaving untouched, human resting
CD4+ T cells of >90% purity. In total, 1.6×107 cells were isolated from 16 mice.
Based on treatment, suppression status, and fetal liver donor used for human
reconstitution, the samples were combined into 10 independent groups for
culturing. The isolated resting CD4+ T cells were plated with MOLT4/CCR5 target
cells as previously described(Laird et al., 2013) and kept in culture for 28 days.
P24 from culture supernatant was measured by ELISA at days 14, 21, and 28.

4.15 p24 stain and viral cell quantification

To determine the number of productively infected cells, mice were sacrificed and
the spleen was homogenized into a single cell suspension. Human CD45+ cells
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were positively selected by staining with human CD45-PE (20 µl per spleen),
then incubating with anti-PE microbeads, and binding to a magnetic column.
Immediately following collection of cells from the magnetic column, cells were
counted using AccuCheck Counting Beads (Invitrogen). Cells were stained with
anti-human CD45-PE, anti-mouse CD45-A780, anti-human CD3-Pacific Blue,
anti-human CD4-APC, anti-human CD8-A700, anti-human CD69-PE/Cy7, antihuman HLA-DR-BV605, followed by fixation/permeabilization, and stain with antip24-FITC (1:100). Flow cytometry analysis was performed with a LSRFortessa
(BD) and FlowJo software (Tree Star).
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